

REVIEW

Open Access



Potential clinical utility of liquid biopsies in ovarian cancer

Jie Wei Zhu^{1,2}, Parsa Charkhchi¹ and Mohammad R. Akbari^{1,3,4*}

Abstract

Background: Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. One of the main challenges in the management of OC is the late clinical presentation of disease that results in poor survival. Conventional tissue biopsy methods and serological biomarkers such as CA-125 have limited clinical applications. Liquid biopsy is a novel sampling method that analyzes distinctive tumour components released into the peripheral circulation, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), tumour-educated platelets (TEPs) and exosomes. Increasing evidence suggests that liquid biopsy could enhance the clinical management of OC by improving early diagnosis, predicting prognosis, detecting recurrence, and monitoring response to treatment. Capturing the unique tumour genetic landscape can also guide treatment decisions and the selection of appropriate targeted therapies. Key advantages of liquid biopsy include its non-invasive nature and feasibility, which allow for serial sampling and longitudinal monitoring of dynamic tumour changes over time. In this review, we outline the evidence for the clinical utility of each liquid biopsy component and review the advantages and current limitations of applying liquid biopsy in managing ovarian cancer. We also highlight future directions considering the current challenges and explore areas where more studies are warranted to elucidate its emerging clinical potential.

Introduction

Ovarian cancer is the third most common gynecologic malignancy worldwide and is associated with the highest mortality rates among gynecologic cancers [1]. Each year, more than 240,000 new cases are diagnosed, and 150,000 women die from ovarian cancer, with five-year survival rates below 45% [2]. Ovarian cancer encompasses a heterogeneous group of neoplasms classified based on distinctive histopathological and molecular characteristics. Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer that is further classified into four major subtypes based on tumour cell morphology: serous, endometrioid, clear cell, and mucinous [3].

Ovarian cancer has also been classified into two subtypes with distinct molecular profiles and clinical courses

(Fig. 1). Type I tumours are low-grade, more indolent, and less aggressive tumours that are characterized by mutations in mitogen-activated protein kinase (MAPK) regulator pathways (e.g. KRAS or BRAF) [4]. In contrast, Type II tumours such as high-grade serous ovarian cancer (HGSOC) are aggressive and have high genetic instability. These are associated with high mutation rates in *TP53*, somatic and germline *BRCA1/2* and other homologous recombination genes [5]. Identifying the unique tumour mutational profile can guide treatment decisions and the selection of appropriate targeted therapy. For example, polyadenosine diphosphate (ADP)-ribose polymerase inhibitor (PARPi) treatment confers a significant progression-free survival (PFS) benefit in patients with a germline or somatic *BRCA1/2* mutation by causing an accumulation of double-stranded DNA breaks and cell death [6–8].


The high morbidity and mortality in ovarian cancer are related to the late diagnosis of disease and decreased effectiveness of surgical or pharmacological therapies.

*Correspondence: mohammad.akbari@utoronto.ca

¹ Women's College Research Institute, Women's College Hospital, University of Toronto, 76 Grenville St, Toronto, ON M5S 1B2, Canada
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Due to the late onset of symptoms and their nonspecific nature, up to 75% of ovarian cancer cases are diagnosed with advanced disease, of which only about 20% will live up to 5 years from the time of diagnosis [9, 10]. The current standard of care for ovarian cancer is cytoreductive surgery followed by platinum-based chemotherapy [11]. Although patients initially respond well to treatment, most patients with advanced ovarian cancer relapse and develop chemoresistance within a few years [12].

There has been an ongoing search for diagnostic, prognostic, or predictive biomarkers to improve ovarian cancer management in the last few decades. Although CA-125 is currently the best-characterized biomarker in ovarian cancer, its sensitivity, specificity, and survival benefit are insufficient for routine screening purposes [12, 13]. Temporal monitoring of CA-125 during follow-up has also not demonstrated benefit in overall survival (OS) [12]. Similarly, tissue biopsies are not feasible as they are highly invasive and only provide localized sampling with limited sensitivity. These shortcomings of existing screening and detection methods have resulted in a continued search for more specific and sensitive biomarkers for ovarian cancer.


In the last decade, liquid biopsies that measure various tumour components, including circulating tumour DNA (ctDNA), cell-free RNA (cfrRNA), circulating tumour cells

(CTCs), tumour educated platelets (TEPs) and exosomes, have become recognized as a method for molecular screening and earlier diagnosis of ovarian cancer (Fig. 2). Compared to traditional tissue biopsies, liquid biopsy is minimally invasive and serial blood samples can be collected over time to monitor cancer progression in real-time. This review discusses the advantages and current limitations of liquid biopsy in the management of ovarian cancer. It will also explore different components and techniques of liquid biopsy, and its utility in ovarian cancer diagnosis, prognosis, and clinical monitoring of treatment response or recurrence.

Liquid biopsy components

CTC: physiologic characteristics and analysis

CTCs are cancer cells found in peripheral blood that intravasate or are passively shed from a primary or metastatic solid tumour site. Several analytic methods for CTC isolation have been developed and validated for ovarian cancer that are based on various biological (i.e., positive epithelial markers, negative hematopoietic markers) or physical properties (i.e., size, density, deformability, electric charges, and invasive capacity) [14–29]. The ability to detect CTCs in the bloodstream has important prognostic implications in ovarian cancer for identifying potential micrometastasis, pre-neoplastic lesions,



tumour heterogeneity, and tumour evolution over time [30–33].

Isolation of CTCs from peripheral blood samples is technically challenging given the low concentration with approximately 1 CTC in 1,000,000 circulating cells [34–36]. Following release from the primary tumour, CTCs overcome several obstacles to survive in the systemic vasculature and spread to distant organs [37]. First, tumour cells shed from solid tumours often traverse the endothelium to enter the circulation by undergoing the epithelial-to-mesenchymal transition (EMT) process. EMT is a phenotypic transformation of epithelial cells with loss of polarity, morphology, and cell markers such

as the epithelial cell adhesion molecule (EpcAM), to gain the migratory and invasive properties of mesenchymal cells [38]. After dissociation from a primary model V₂ carcinoma (established from skin carcinoma of cottontail rabbits) site of 1 cm, approximately one million CTCs intravasate via dermal invasion into the peripheral circulation each day, of which < 1% typically remain viable for metastasis [39]. Most CTCs undergo apoptosis or necrosis due to the profound environmental challenges in the bloodstream such as starvation, shear stress, and immunological detection [40]. Only a small proportion of CTCs can survive through upregulation of several signaling pathways, including increased secretion of growth

factors, downregulation of death receptors, and over-expression of anti-apoptotic ligands [39]. CTCs must also evade natural immune system defences and natural killer (NK) cell recognition. According to the adaptive immune resistance theory, tumour cells avoid activation of the antitumor response from NK cells and T cells by upregulating the naturally occurring programmed death-ligand 1 (PD-L1). They also avoid phagocytosis by macrophages through the upregulation of CD47 [41–43].

Currently, the CellSearch detection system is the most widely used isolation strategy with US Food and Drug Administration (FDA) approval. CellSearch uses an immunoaffinity-based isolation strategy to identify CTCs based on positive EpCAM expression [44]. However, the application of CellSearch in ovarian cancer may be limited in the setting of low EpCAM expression. In a study with newly diagnosed or recurrent ovarian cancer patients, Liu et al. found no correlation between serial CTC enumeration by the CellSearch system and clinical outcomes [15]. One possible explanation is the downregulation of EpCAM during EMT or the heterogeneous expression of cell surface markers in ovarian cancer [15]. Obermayr et al. also reported EpCAM expression in a small proportion of EOC patients [21]. The researchers used RT-qPCR to analyze EpCAM expression of CTCs isolated using density gradient centrifugation from 216 EOC patients before and after primary treatment compared to 39 healthy controls. The researchers reported EpCAM expression in only 8% of patients at baseline before treatment and 4% for patients after six months of adjuvant chemotherapy.

To overcome these limitations, alternative approaches targeting various biophysical properties of CTCs such as cell size and invasive potential have been developed [14, 29]. For example, Yang et al. recently used a technique called CanPatrol enrichment, in which CTCs were filtered through 8- μ m porous membranes and detected using RNA in situ hybridization (RNA-ISH). CTC subpopulations were identified using epithelial (EpCAM and CK8/18/19), mesenchymal (vimentin and Twist), and epithelial-mesenchymal hybrid markers [14]. The researchers used hybrid markers and found a mean CTC count of 8.70 ± 5.69 detected in 5 mL of blood among stage 1-IV EOC patients that was significantly higher compared to controls with benign gynecologic diseases (1.04 ± 0.73). Multivariate analyses demonstrated both higher CTC counts and higher percentage of mesenchymal CTC were independent prognostic factors for significantly lower OS ($p = 0.012$ and $p = 0.009$ respectively). Fan et al. proposed another novel enrichment method utilizing the unique property that blood containing CTCs will invade and ingest Cell Adhesion Matrix (CAM) while non-tumour and dead tumour cells do not [29]. The researchers used

a cell invasion assay that enriches and identifies tumour cells based on CAM invasion (CAM+) and expression of standard epithelial markers (Epi+) to analyze peripheral blood samples of 71 suspected ovarian cancer patients. The study found a significantly higher mean CTC count in stage III/IV patients at 41.3 CTCs/ml compared to 6.0 CTCs/ml in stage I/II patients and 0 CTCs/ml in benign patients (p -value = 0.001). Kaplan Meier analysis showed a significantly lower disease-free survival in patients with detectable CTCs with a median survival of 15.0 months compared to 35.0 months in those without detected CTCs ($p = 0.042$). Other novel techniques include modified immunoaffinity-based strategies targeting several ligands at once (e.g. EpCAM, folate receptor alpha, Human epidermal growth factor receptor 2) and nanoparticles conjugated with the antibody against Mucin 1 (MUC1) [45, 46]. Given the rarity of CTCs in peripheral circulation despite their prognostication potential, further studies are required to optimize the detection and isolation of CTCs in ovarian cancer.

cfDNA/ctDNA: physiological characteristics and analysis

Normally, plasma contains cfDNA that is passively released from necrotic or apoptotic cells, while ctDNA is the cfDNA secreted from cancer cells. In healthy individuals, cfDNA concentrations are elevated following tissue damage such as intense exercise, inflammation, sepsis, surgery, radiotherapy, trauma, or during pregnancy [47–49].

Compared to CTCs, cfDNA concentrations are higher in blood, making them suitable targets for liquid biopsy [50]. Tumours harbour unique somatic genetic alterations that help in distinguishing ctDNA from noncancerous cfDNA [47, 48]. The majority of cfDNA is expected to originate from healthy cells, while a variable amount of cfDNA (0.01–93%, depending on the tumour size) can originate from cancer cells (ctDNA) [51, 52]. However, a popular hypothesis posits that a large fraction of cfDNA is released from cells in the tumour microenvironment that were destroyed due to hypoxia or the antitumour response [53]. Recent studies confirmed that cfDNA levels in the blood are higher among ovarian cancer patients with an average of 180 ng/mL compared to 30 ng/mL in healthy controls or individuals with benign ovarian pathologies [54–56]. Therefore, increased amounts of cfDNA may serve as a diagnostic tool for ovarian cancer, while genomic analysis of ctDNA may provide valuable prognostic and predictive information [57, 58].

The mechanism of cfDNA released from cells into the circulation remains unclear, although apoptosis and necrosis are the most widely accepted hypotheses based on cfDNA properties. Previous studies have estimated the size of cfDNA to vary from ~40–200 base pairs (bp),

with a peak at around 166 bp [53, 59–61]. Agarose gel electrophoresis to separate extracted cfDNA has found fragment ladders ranging from 160 bp up to 21 kbp [61, 62]. The size of these fragments corresponds primarily to mono- and oligonucleosomes that are characteristic of caspase-dependent cleavage during apoptosis [59, 61–63]. In contrast, DNA fragments larger than 10 kb are thought to be a result of necrotic cell death in tumours with different kinetics and amount of cfDNA released from different necrosis-inducing agents [64–66]. However, this theory has been called into question following studies reporting that radiation therapy, which typically induces tissue necrosis, results in a reduction of cfDNA levels by up to 90% in the plasma of cancer patients [67, 68]. Other proposed cfDNA release mechanisms include active secretion in living cells with the expulsion of nuclei, phagocytosis, neutrophil extracellular trap release (NETosis), and excision repair [69–74].

Once released into the bloodstream, the size, integrity, and half-life of cfDNA have important clinical implications in diagnosis and tumour detection. One challenge currently is the small amount of ctDNA in the blood compared to cfDNA released from normal cells, particularly when the tumour size is small. Since a significant proportion of ctDNA is released from necrotic cancer cells, the cfDNA size in cancer patients is generally longer than those of healthy individuals. However, the length of ctDNA released from apoptotic cancer cells is shorter than cfDNA released from the normal cells due to apoptosis, with a mean of 133–144 bp [75]. ctDNA enrichment may therefore be possible based on a size selection approach. Selecting shorter DNA fragments between 90–150 bp improved the detection of ctDNA with up to 11-fold enrichment of mutation allele fraction [61, 75, 76]. In addition, the distribution of differently sized DNA fragments has implications for disease staging as an indicator of cfDNA Integrity (cfDI). The cfDI is defined as the ratio of long (released from necrotic cells) to short (released from apoptotic cells) cfDNA fragments. cfDI is calculated by measuring long and small ALU sequence fragments (ALU₂₄₇ and ALU₁₁₅ respectively) using qPCR [77]. Studies have shown that cancer patients have a higher cfDI compared to healthy controls or individuals with benign disease [78, 79]. Higher integrity is associated with increased levels of necrotic cell death in advanced disease with larger and more aggressive tumours [78, 80].

The short half-life of cfDNA present in the bloodstream allows for real-time analyses of the tumour mutational profile. The level of cfDNA in circulation at any given time is determined by the net amount of DNA released minus DNA clearance. cfDNA clearance may occur in organs including the liver, spleen, kidney, or lymph nodes

[81]. In the bloodstream, circulating enzymes such as DNase I, plasma factor VII-activating protease (FSAP), and factor H are responsible for cfDNA breakdown [82, 83]. Rapid clearance of apoptotic cells and cfDNA normally allow for healthy individuals to have low levels of cfDNA. In cancer patients, cfDNA accumulates due to impaired clearance that is currently poorly understood. Using fetal DNA in postpartum maternal circulation, Lo et al. estimated the half-life of cfDNA to be approximately 4 to 30 min, which has been consistent across other studies [84–87]. However, the half-life of cfDNA may vary depending on several factors, including interactions with molecular complexes that interfere with cfDNA degradation, tumour stage and subtype, and treatment [69, 81]. Interestingly, one study used next-generation sequencing (NGS) technology to examine the kinetics of cfDNA and found that the clearance of cfDNA may occur in a biphasic manner. The first rapid phase has a mean half-life of an hour, followed by a second slow phase with a mean half-life of 13 h [88].

Several technologies have been developed for ctDNA detection in blood, including quantitative PCR, digital droplet PCR (ddPCR), and NGS for targeted sequencing or whole-genome sequencing (WGS). In addition to quantitative changes, these technologies detect qualitative changes in ctDNA, which include tumour-specific variants (TSVs), gene fusion, copy number variations, aberrant DNA methylation, and chromosomal instability. The development of NGS and digital polymerase chain reaction (dPCR) has improved the sensitivity and specificity of ctDNA detection. To date, most ctDNA detection methods have focused on high-grade serous ovarian cancer (HGSOC) patients with targeting TP53 mutations [45, 89–91]. One study used targeted error correction sequencing (TEC-Seq) to examine 58 cancer-related genes encompassing 81 kb and reported the highest sensitivity and specificity at 75–100% and >80%, respectively [89]. In stage I-II disease, the highest detection rate was 68% with a specificity of 100% that was achieved using TEC-Seq and ddPCR combined. The high specificity achieved in this study may be attributable to TEC-Seq advantages for using deep sequencing for more direct evaluation of sequence changes. In fact, deep sequencing using random unique molecular barcodes annealed to each DNA template fragment has been the preferable method for detecting low-level signatures of TSVs in liquid biopsies [92]. Duplex sequencing using molecular barcodes on both DNA strands for removing sequencing errors that are in one strand only has improved variant detection accuracy by >10,000 times compared to conventional NGS [93, 94].

Although ctDNA analysis with plasma samples is currently the preferred method, alternative approaches have

utilized different sources. In 2013, Kinde et al. examined the ability of the liquid Pap test with uterine cervix sampling to detect ovarian and uterine cancers. The researchers used massively parallel sequencing for TSVs using a 12-gene panel and found ctDNA in 41% (9 of 22) of ovarian cancer patients [95]. Similarly in 2018, Wang et al. analyzed Pap brush samples from 245 ovarian cancer patients using PapSEEK with an assay for mutation in 18 genes and reported a limited detection sensitivity of 33%, including 34% for patients with stage I–II disease [96]. Likewise, Maritschnegg et al. conducted a study with uterine cavity lavage samples from EOC patients and benign gynecologic patients [97]. The researchers used NGS for sequencing *AKT1*, *APC*, *BRAF*, *CDKN2A*, *CTNNB1*, *EGFR*, *FBXW7*, *FGFR2*, *KRAS*, *NRAS*, *PIK3CA*, *PIK3R1*, *POLE*, *PPP2R1A*, *PTEN*, and *TP53* genes to analyze lavage samples. Using NGS, the researchers reported detectable mutations, mainly in *TP53*, in 60% of ovarian cancer patients and an improved ctDNA detection rate of up to 80% with more sensitive methods of digital droplet polymerase chain reaction (ddPCR) and the Safe-sequencing system (SafeSeqS). Interestingly, the study also found *TP53* mutations in lavage samples of all 5 patients with stage IA disease. Building on these results, the same team conducted a study in 2018 demonstrating the feasibility of this technique that found a median absolute amount of 2.23 μg cfDNA in uterine and tubal lavage samples and TSVs using deep-sequencing in 80% (24 of 30) of ovarian cancer patients [27]. Given these findings, the molecular analysis of uterine lavage samples may be a potential technique for the early diagnosis of ovarian cancer. Other novel techniques including peritoneal washing, urine sampling, and vaginal sampling have been utilized for ctDNA profiling. However, such methods require more research to elucidate their diagnostic utility in ovarian cancer [98–101].

cfRNA: cell-free mRNA, miRNA, circRNA and lncRNA

The rapid turnover of tumours results in high gene transcription and shedding of high amounts of cfRNA consisting of mRNA and microRNA (miRNA) into the circulation [102]. Normal and tumour cells secrete miRNAs into various body fluids, including plasma, urine and vaginal discharge, and breast milk [103]. In the blood, mRNA and miRNA are bound to specific ribonucleoprotein complexes, high-density lipoproteins, platelets, or packaged in extracellular vesicles (EV) such as exosomes to avoid degradation and acquire more stability [103, 104]. Several studies have suggested the role of miRNAs in tumorigenesis, cell differentiation, proliferation, inhibition of angiogenesis, metastasis, and apoptosis. Importantly, the biogenesis and activation of miRNAs are faster with longer half-lives compared to mRNA and proteins,

which may make miRNAs more suitable for earlier diagnosis of ovarian cancer [105–108].

The diagnostic, prognostic, and therapeutic potential of circulating miRNAs in ovarian cancer have been explored in many studies. In 2008, Taylor et al. first reported that higher levels of 8 exosomal miRNAs (miR-21/141/200a/200b/200c/203/205/214) were found in the serum of ovarian patients compared to healthy controls, although there was no significant difference in early versus late-stage ovarian cancer [109]. These findings were subsequently supported by several other studies reporting that serum miRNAs (miRNA-141/200a/200b/200c) were upregulated in ovarian cancer patients compared to normal or benign tumour controls [110, 111]. Gao et al. also found that different miRNA-200c expression levels may correlate with ovarian cancer staging, with more advanced tumours having lower miRNA-200c levels and higher miRNA-141 [110]. However, Kim S. et al. analyzed seven serum exosomal miRNAs and concluded that the expression of miRNA-141, 200a, and 200b were too low to be an appropriate serologic biomarker [112].

Although miRNA-145 was identified as the best-performing single marker with a sensitivity of 91.7% and accuracy of 86.8%, similar changes in miRNA-145 levels were observed in other malignancies besides ovarian cancer [112, 113]. The lack of discrimination between cancer types suggests that single miRNAs are unlikely to be a reliable biomarker. To overcome these challenges, a recent study by Elias et al. was the first to combine NGS analysis of serum circulating miRNA with a machine learning technique called a neural network model and developed a diagnostic algorithm for EOC. The study authors reported an AUC value of 0.90 for this model, which was significantly higher compared to CA-125. This study suggests the potential for a new era of machine-learning application in biomarker discovery [114].

In 2017, Yokoi et al. performed miRNA sequencing to identify the optimal combination of candidate circulating miRNAs for the early detection of ovarian cancer [115]. This study identified eight miRNAs with RT-qPCR validation and statistical cross-validation with a large research cohort. The predictive model using a combination of 8 circulating serum miRNAs was able to differentiate early-stage ovarian cancer from benign tumours with 86% sensitivity and 83% specificity, and from healthy controls with 92% sensitivity and 91% specificity [115]. In a later study, the same research team analyzed 4,046 serum samples from 333 ovarian patients, 95 benign or borderline ovarian tumours, 2,759 healthy controls and 859 other solid cancers using miRNA microarray [116]. The study found that combined miRNAs can successfully discriminate ovarian from lung, gastric, breast, hepatic, colorectal, and pancreatic cancers, but not sarcoma or

esophageal cancer. In this study, utilization of circulating miRNA yielded a sensitivity of 99% and a specificity of 100% for discriminating between ovarian cancer and healthy controls. This was the first large-scale comprehensive study examining circulating miRNAs in ovarian cancer and reported promising miRNA combinations for the detection of early-stage disease.

In addition to miRNA, circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) also demonstrated potential utility as biomarkers for liquid biopsy in ovarian cancer. circRNAs have a covalently closed loop structure and lncRNAs have transcript sizes of >200 nucleotides, which allow increased stability and resistance against RNase degradation in the peripheral circulation. circRNAs are abundant and diverse, with a half-life >48 h, that facilitate easier detection [117–119]. circRNA expression differs between primary and metastatic sites and is thought to play a role in regulation of ovarian cancer. A recent study found that the expression levels of circular RNAs are inversely associated with activating many signalling pathways involved in tumour metastasis (i.e., NF- κ B, PI3k, AKT, and TGF- β) [120]. Using RT-qPCR in a sample of 83 EOC patients compared to 166 benign or healthy controls, Hu and colleagues found that CircBNC2 was associated with histological grade, serous subtype, and distant metastasis [121]. Similarly, lncRNAs were found to contribute to the early pathogenesis, progression, metastasis and chemoresistance of recurrent ovarian cancer [122–124]. Although there is emerging evidence suggesting an association between differing expression levels of lncRNAs (H19, LSINCT5, XIST, CCAT2, HOTAIR, AB073614, and ANRIL) and clinical progression or treatment response of ovarian cancer, the diagnostic sensitivity and specificity of lncRNAs remain to be fully elucidated [125–130]. To date, no lncRNA has been approved for clinical utility and further research is required to identify the most clinically relevant candidates with cancer-enriched or specific signatures in ovarian cancer.

TEPs: RNA content

Tumour-educated platelets (TEPs) play an important role in local and systemic responses to tumour growth. Platelets are normally anucleate, although they may contain residual mRNA and miRNA derived from their megakaryocyte precursors or captured from intercellular interactions in the circulation. Platelet education denotes the transfer and sequestration of biomolecules from tumour cells into platelets [131, 132]. External factors in the tumour microenvironment such as stromal and immune cell signals may activate platelet surface receptors to induce specific splice events of pre-messenger RNAs (pre-mRNAs) in circulating platelets [133,

134]. Key advantages of TEPs include their high abundance, easy isolation, and high-quality RNA that may be processed according to external signals. Therefore, TEPs have a dynamic mRNA repertoire with both specific splice events in response to external signals and direct ingestion of spliced circulating mRNA that may provide useful diagnostic information in ovarian cancer. Best et al. first studied the diagnostic potential of TEPs by mRNA sequencing in patients with various cancers [135]. This study found that TEPs were able to distinguish cancer patients from healthy controls with a high accuracy of up to 96% and detect the primary tumour location with 71% accuracy. Later, Piek et al. concluded that TEPs can differentiate early stage ovarian cancer from benign pathologies with 80% accuracy [136]. An ongoing clinical trial (NCT04022863) may further build upon these results by examining the accuracy of TEPs and ctDNA in determining the nature of ovarian tumours and provide information on its diagnostic potential [137]. Interestingly, a recent retrospective cohort study by Giannakeas et al. examined the association between thrombocytosis (platelet count greater than $450 \times 10^9/L$) and cancer. By studying 53,339 adults aged 40–75 years who developed thrombocytosis with normal platelet count in the previous 2 years and no malignancy history, they estimated the risk of cancer in a 10-year follow-up period [138]. The authors reported that the 2-year relative risk (RR) was highest for ovarian cancer (RR = 7.11; 95% CI, 5.59–9.03), while the 6-month RR for developing ovarian cancer was even higher (RR = 23.33; 95% CI, 15.73–34.61). In the future, TEPs profiling with complementary ctDNA/CTC analysis and platelets quantification may potentially be a blood-based method for cancer diagnostics.

Exosomes: content analysis

Interest in the diagnostic and prognostic potential of exosomes has increased in recent years. Exosomes are extracellular vesicles (EVs) typically 30–100 nm in diameter. Such vesicles are extremely stable and can survive under extreme conditions. Exosomes are released from both normal and tumour cells. Likewise, they are found in various body fluids, such as saliva, plasma, urine, ascites, and cerebrospinal fluid [139]. Exosomes can participate in local and distant signalling by fusing with the membrane of the recipient cell or attaching to receptors on the cell's surface. In cancer, exosomes have the ability to enhance tumorigenesis [140], help tumour cells escape the immune system [141], and cause treatment resistance [142]. Likewise, exosomes can enter the circulation and increase the likelihood of metastasis by preparing distant tumour microenvironments [143, 144]. Exosomes have been also used as therapeutics to successfully eliminate tumour cells [145]. Furthermore, exosomes contain

tumour-specific proteins, lipids, DNA, and RNA making them potential diagnostic biomarkers in cancer. For example, exosomes with heat shock protein (HSP70) expressed on their membrane, are observed more in ovarian, breast, and lung cancer samples compared to healthy controls [146]. Additionally, studies have shown increased total exosome concentrations in serum samples of EOC patients [109, 111].

Exosomes can carry significant quantities of miRNAs. Multiple studies have observed differences between the miRNA profiles of exosomes in EOC patients and healthy controls. Meng et al. showed that the concentrations of miR-200b and miR-200c are higher in exosomes obtained from patients with stage III–IV EOC and are associated with significantly shorter OS [111]. Another study showed that the miRNA profiling of circulating exosomes using a modified magnetic-activated cell sorting (MACS) technique can differentiate between benign and malignant ovarian tumours [109]. Additionally, exosomes derived from EOC patients have higher concentrations of TGFB1 and melanoma-associated antigen 3 (MAGE3) and MAGE6 [147]. EOC exosomes also have a higher concentration of Claudin 4 that is associated with tumour stage and CA125 levels [148]. CD24 and EpCAM were also shown to be elevated in exosomes isolated from EOC plasma samples [149]. Furthermore, Liang et al. identified 2,230 proteins in exosomes secreted from OVCAR-3 and IGROV1 ovarian cancer cell lines. Many of these identified proteins were involved in tumorigenesis and metastasis, indicating the prognostic potential of exosomal profiling [150]. Overall, exosomal profiling can act as a cancer-specific diagnostic and prognostic biomarker and replace invasive cell biopsies. However, more comprehensive clinical studies are required to determine the clinical value of this approach.

Clinical applications of liquid biopsy for ovarian cancer

Liquid biopsy is a non-invasive method with emerging evidence for its utility in screening and longitudinal monitoring of ovarian cancer. Different tumour components may be analyzed within collected plasma samples to provide earlier diagnosis, prognostication, molecular targets for therapy, and detection of resistance to treatment (Fig. 3). A summary of the key advantages, disadvantages and main clinical applications of each liquid biopsy component is provided in Fig. 4.


Early diagnosis of ovarian cancer

The early detection of ovarian cancer is critical in reducing mortality and morbidity. Staging is the most important prognostic factor in determining recurrence-free survival (RFS), with stage I or II diseases

having significantly longer RFS and OS compared to more advanced stages [151]. Therefore, biomarkers that allow for the diagnosis of OC in stages I-II may extend survival and improve patient outcomes.

Two-thirds of EOC cases are diagnosed at advanced stages, with a significantly worse prognosis [152]. Interestingly, several studies have suggested the diagnostic potential of promoter methylation that leads to epigenetic inactivation of tumour suppressor genes as an early event during ovarian cancer pathogenesis [153–160]. Analysis of ctDNA methylation status in pre-operative plasma samples from ovarian cancer patients with both early (stage I-II) and advanced-stage disease (stage III-IV) demonstrated a significant association with abnormal methylation of tumour suppressor genes compared to healthy controls [154, 157, 158]. Specifically, the detection of hypermethylation in promoter regions of tumour suppressor genes *RUNX3*, *TFPI2*, *RASSF1* and *RASSF2* from plasma samples has been reported for the diagnosis of ovarian cancer, although these markers are also implicated in other cancers [153–160]. Despite the potential for identifying aberrant gene promoter methylation to detect malignancies, its utility remains limited by the concentration of extracted ctDNA available for analysis. Earlier stages of EOC are often asymptomatic and are correlated with lower concentrations of ctDNA [159, 160]. There is currently limited evidence regarding the application of liquid biopsy for the early detection of ovarian cancer at pre-symptomatic stages. Only one study by Widschwendter et al. conducted in the early screening setting reported that methylation in a set of epigenetic markers including *COL23A1*, *C2CD4D* and *WNT6* is able to detect EOC up to 2 years before clinical diagnosis with a sensitivity of 23% and specificity of 97% [161]. This study used reduced representation bisulfite sequencing (RRBS) to analyze samples collected from 100,000 asymptomatic women and 43 cases of ovarian cancer. It remains difficult to conduct screening studies for EOC due to the relatively low incidence and large sample sizes required.

Other approach is looking for gene mutations rather than methylation changes. The sensitivity and specificity of mutation detection are important considerations when applying liquid biopsies for the early diagnosis of ovarian cancer. ctDNA has better diagnostic performance compared to traditional CA-125 with several studies demonstrating that quantitative analysis of ctDNA has a relatively high specificity of 88% and sensitivity ranging from 27–100% [92, 162–168]. A recent systematic review of 23 studies evaluating ctDNA for the diagnosis of EOC in symptomatic patients preoperatively yielded similar results [89, 96, 153, 154, 156–158, 160–162, 166, 167, 169–179]. Other studies that evaluated ctDNA



analysis in HGSOC patients for *TP53* mutation detection, reported high sensitivity (75–100%) and specificity (>80%) [45, 89–91]. For stage I-II disease, Phallen et al. observed a sensitivity of 68% and a specificity of 100%. The researchers used TEC-Seq and ddPCR for ctDNA detection and found detectable mutations in driver genes for over two-thirds of stage I-II ovarian cancer cases [89]. More recently, Barbosa et al. used NGS and a custom panel of 27 genes to analyze tumour and matched plasma samples from 96 ovarian cancer patients and detected tumour somatic variants in 75% of patients with stage I disease [180]. Cohen et al. analyzed circulating protein biomarkers and genetic alterations in cfDNA using a commercial blood test called CancerSEEK [177]. This test used 61 amplicons for massively parallel sequencing to increase sensitivity while minimizing any changes in specificity. The authors reported that ctDNA detected in ovarian cancer with a sensitivity of 98% and specificity

of 99%, however, the early-stage detection rate was only 38% [177].

CTC is another liquid biopsy component that has been studied for early EOC detection. Zhang et al. used immunomagnetic bead screening, targeting epithelial markers EpCAM, HER2, and MUC1 on ovarian cancer cells, combined with multiplex RT-qPCR analysis of isolated mRNA from CTCs and tumour tissues for detecting CTCs in 109 EOC patients. This study showed that patients with stage IA-IB disease have a much higher CTC positive rate (93%) compared to the CA-125 positive rate (64%) in the same patients [181]. In 2018, Guo et al. prospectively enrolled 61 women with suspicious ovarian masses to investigate the diagnostic value of CTCs. The researchers used microfluidic isolation and immunofluorescent staining to identify and quantify CTCs and determined the sensitivity of CTCs using receiver operating characteristic (ROC) curve analysis to






Liquid Biopsy Component	Circulating Tumour Cells (CTCs)	Circulating Tumour DNA (ctDNA)	Cell-Free RNA (cfRNA)	Tumour Educated Platelets (TEPs)	Exosomes
					
Main Clinical Application	Diagnosis and prognosis	Diagnosis, prognosis, predicting response to treatment, monitoring response to treatment and detection of recurrence	Diagnosis and prognosis	Diagnosis	Diagnosis, prognosis, and prediction of response to treatment
Advantages	<ul style="list-style-type: none"> • Earlier detection of recurrence or metastasis • Predicting recurrence • Accessible source of tumour RNA/DNA/proteins • Detecting CTCs originating from both primary tumour and metastatic sites • Non-invasive 	<ul style="list-style-type: none"> • Higher available concentrations in bloodstream • Availability of laboratory techniques for analysis (e.g., NGS, ddPCR) • Higher stability compared to other liquid biopsy components • Capturing tumour heterogeneity • Available in a variety of body fluids • Non-invasive 	<ul style="list-style-type: none"> • Providing information on tumour's genetic expression profile • Monitoring tumour expression changes over time • Non-invasive 	<ul style="list-style-type: none"> • Potential use for earlier diagnosis • Routinely available clinical tests for quantification (e.g., CBC) • Non-invasive 	<ul style="list-style-type: none"> • Genomic contents protected from degradation • Accessible and variable source of tumour components • Available in a variety of body fluids • More abundant • Non-invasive
Limitations	<ul style="list-style-type: none"> • Low plasma counts • Difficulty differentiating CTCs from other cells in bloodstream 	<ul style="list-style-type: none"> • Low concentration (ctDNA:cfDNA ratio) in early stages make detection difficult • Difficulty differentiating ctDNA from cfDNA 	<ul style="list-style-type: none"> • More difficulty with isolation compared to cfDNA • Unstable molecule • No reliable methods for reproducible and practical application in clinical setting 	<ul style="list-style-type: none"> • Limited research • Lack of reliable methods for reproducible and practical application in clinical setting 	<ul style="list-style-type: none"> • Lack of standardized isolation methods • Lack of reliable methods for clinical application
Future Directions	<ul style="list-style-type: none"> • Improving methods for detection (e.g., low EpCAM expression settings) • Higher quality studies with larger sample sizes for determining prognostic applications 	<ul style="list-style-type: none"> • Improving methods for enrichment of ctDNA • Optimizing sensitivity for analysis techniques for detection at low allele frequencies • Further studies with larger sample sizes 	<ul style="list-style-type: none"> • Optimal combination of RNA candidates using machine learning methods • Improving methods for stabilizing cfRNA and extraction of cfRNA from plasma • Further studies with larger sample sizes 	<ul style="list-style-type: none"> • More evidence on the diagnostic sensitivity and specificity in different cancers • More standardized methods for analyzing platelet content • Further studies with larger sample sizes 	<ul style="list-style-type: none"> • More evidence on the diagnostic sensitivity and specificity in different cancers • More standardized methods for extraction of exosomes • Further studies with larger sample sizes

Fig. 4 Comparison of five liquid biopsy components and the main advantages, disadvantages, and future directions of their clinical application in ovarian cancer management

be 73.3% with a specificity of 86.7%, which was superior to CA-125 (sensitivity = 56.7%) [182]. The main challenge facing CTC-based diagnostics is the reduced amount of CTCs detectable in circulation with lower tumour burdens at early disease stages [15, 182, 183]. In contrast, advanced stage tumours release more CTCs that often travel with metastatic colonies to distant sites allowing for easier detection. As such, detection of CTCs is significantly associated with advanced stages (III and IV), where the diagnostic performance of CTCs through immunocytochemistry (ICC) has been reported to have a sensitivity of 76–83% and specificity of 55–95% [21, 25,

181, 184, 185]. Compared to benign controls, early-stage (I-II) and late-stage (III-IV) EOC samples are 8.4 and 16.9 times more likely to have CTCs, respectively. Likewise, significantly lower levels of CTCs are found in stage I patients compared to advanced stages [181]. Current studies on utilizing CTC for early diagnosis of ovarian cancer are limited by small sample sizes and future well-powered studies are warranted to confirm these findings.

Although some studies have suggested the diagnostic potential of miRNA expression profiling and exosome analysis in ovarian cancer, further research is required to determine their diagnostic sensitivity and specificity in

early-stage disease. For example, Todeschini et al. analyzed two cohorts consisting of 168 stage III-IV HGSOC patients and 65 healthy controls and demonstrated the clinical potential of miR-1246 as a diagnostic biomarker for HGSOC with a significant increase in the expression of miR-1246 in post-operative serum samples of HGSOC compared to healthy individuals. This study used a novel microarray data normalization to identify candidate diagnostic miRNAs followed by signature validation with RT-qPCR. The study reported a significant over-expression of miR-1246, miR-595, and miR-2278 in HGSOC patients and the highest detection performance for miR-1246, with a diagnostic sensitivity of 87%, specificity of 77%, accuracy of 84%, and AUC of 0.89 [184]. Similarly, the clinical potential of exosomes have also been suggested in ovarian cancer. Zhang et. al analyzed plasma samples from 40 stage III or IV EOC patients versus 40 healthy controls to investigate the role of four exosome proteins including Lipopolysaccharide Binding Protein (LPB), Fibrinogen Gamma Chain (FGG), Fibrinogen Alpha Chain (FGA) and Gelsolin (GSN) as diagnostic biomarkers [186]. This study reported significantly elevated FGA and GSN levels and significantly downregulated FGG and LBP levels in the ovarian cancer group. FGA conferred the highest diagnostic sensitivity among the 4 candidates with an AUC of 0.8459. In another study with 78 EOC patients (63 stage III-IV and 7 stage I-II) and 30 healthy controls, Schwich et al. reported a seven-fold increase in HLA-G levels in plasma circulating exosomes of EOC patients (mean 14.3 ng/mL) compared to healthy controls (1.9 ng/mL) [187]. Therefore, studies to date on miRNA and exosome analysis have been conducted mainly in patients with advanced ovarian cancer, and future research is needed to elucidate their diagnostic utility for early-stage disease. Table 1 summarizes the studies investigating the clinical application of liquid biopsy analytes in ovarian cancer diagnosis.

Detecting recurrence and determining prognosis in ovarian cancer

There is ongoing research examining the clinical application of liquid biopsy to identify microscopic residual disease following primary debulking surgery as a prognostic indicator, predict survival outcomes, and for earlier detection of disease recurrence. Clinically, the implementation of liquid biopsy may aid in selecting individuals at greater risk of relapse for consideration of alternative management approaches and potential inclusion in clinical trials.

The strongest evidence to date on the prognostic utility of liquid biopsy is for ctDNA [188, 189]. Quantitative analysis of ctDNA demonstrate that ctDNA concentrations are positively correlated with advanced stages of

EOC and may indicate response to treatment [188–192]. ctDNA concentrations are more associated with earlier progression and decreased response to treatment than CA-125 or imaging [162–164, 193]. Pereira et al. used qPCR and targeted sequencing to quantify ctDNA levels immediately following surgery in 22 EOC patients. This study found that undetectable levels of ctDNA at 6 months postoperatively were associated with significantly improved PFS ($P=0.001$) and OS ($P<0.05$) [163]. Another study examining *TP53* mutations in ctDNA of relapsed HGSOC patients highlighted the prognostic ability of *TP53*, with a less than 60% decrease in *TP53* mutant allele fraction after one cycle of chemotherapy associated with poor response and shorter PFS compared to a decrease of more than 60% [164]. Similarly, a recent study with 48 HGSOC patients found that approximately 80% of patients classified as having no surgical residual disease had detectable ctDNA. This study reported that these patients had a higher mortality risk compared to those who did not have detectable post-surgery ctDNA with a 5-year survival rate of 58.3% for those with detectable ctDNA, compared to 85.7% for those with undetectable ctDNA [193]. Although most studies were limited by small sample sizes, all authors concluded that analyzing ctDNA through liquid biopsy has potential as a prognostic biomarker in clinical settings.

Furthermore, there is also evidence supporting the role of ctDNA in detecting recurrent disease. Up to 85% of EOC patients can experience recurrence following first-line therapy. Recurrence of EOC limits the survival of patients and is often referred to as incurable. CA-125 and imaging techniques such as CT and PET-scans are used as traditional recurrence markers [194]. However, recent studies have shown that ctDNA quantification can potentially improve the detection of relapse compared to traditional imaging techniques and CA-125 [188, 190]. Similarly, Parkinson et al. examined *TP53* mutations in ctDNA of relapsed HGSOC patients and reported that ctDNA was detected at ≥ 20 amplifiable copies/mL of plasma in nearly all relapsed patients with disease volume $> 32 \text{ cm}^3$ [164]. Likewise, Minato et al. detected ctDNA in all patients with recurrent EOC using droplet digital PCR, while no ctDNA was detected in recurrence-free patients. In the majority of cases, ctDNA was detected before CA-125 levels indicated recurrence [195]. These results are consistent with the study by Pereira et al. that reported a mean predictive lead time of 7 months for ctDNA over CT imaging for the detection of recurrence [163]. As a result, ctDNA has the potential to be used as an early detection tool for EOC recurrence.

CTCs have also demonstrated prognostic potential in ovarian cancer. In a study by Marth et al., immunobeads coated with MOC-31 antibodies were used to

Table 1 Liquid biopsy analytes and potential utility as diagnostic biomarkers

Analyte	Author, Year	Tumour Subtype and Staging	Number of patients	Laboratory Technique	Detection Rate	Ref	
CTCs	Zhang et al., 2018	Stage I-IV EOC	109	Immunomagnetic bead screening, Multiplex RT-PCR	90%	[181]	
	Guo et al., 2018	Stage I-IV EOC	30	Microfluidic isolation and immunofluorescent staining	73%	[182]	
	Pearl et al., 2014	Stage I-IV EOC	129	CAM-based identification platform	Sensitivity = 83% PPV = 97.3%	[184]	
	Poveda et al., 2011	Stage I-IV EOC	216	CellSearch system and reagents (Veridex)	14.4% had 2 or more CTCs prior to therapy	[183]	
	Pearl et al., 2015	Stage I-IV EOC	123	iCTC flow cytometry assay	Sensitivity = 83% Specificity = 97%	[185]	
ctDNA	Wang et al., 2017	Stage I-IV EOC	194	QIAamp DNA blood mini kit, promoter methylation OPCML, TFPI2 and RUNX3	Sensitivity = 90.14 Specificity = 91.87	[154]	
	Dong et al., 2012	Stage I-IV EOC	36	Methylation-specific PCR	80.6%	[158]	
	Wu et al., 2014	Stage I-IV EOC	47	Methylation-specific PCR	51.1%	[156]	
	Bondurant et al., 2011	Stage I-IV EOC	106	Methylation-specific PCR	51%	[159]	
	Liggett et al., 2011	Stage III-IV EOC	30	Microarray-mediated methylation assay	Sensitivity = 90.0% Specificity = 86.7%	[160]	
	Widschwendter et al., 2017	Stage I-IV EOC	43	Reduced representation bisulfite sequencing	Sensitivity = 23% Specificity = 97%	[161]	
	Forsheew et al., 2012	Stage III-IV EOC	46	Targeted deep sequencing	Sensitivity = 97.5% Specificity = 97.5%	[162]	
	Du et al., 2018	Stage II-III EOC	21	High-throughput sequencing	Sensitivity = 73.7% Specificity = 100%	[165]	
	Vanderstichele et al., 2017	Stage I-IV EOC	57	Whole-genome sequencing	Sensitivity = 2- to fivefold higher than CA-125 Specificity = 99.6%	[166]	
	Cohen et al., 2016	Stage I-IV EOC	32	DNA sequencing and whole genome NIPT	Sensitivity = 40.6% Specificity = 93.8%	[167]	
	Wang et al., 2015	Stage I-IV EOC	114	Multiplex nested methylated specific PCR	Sensitivity = 90.14% Specificity = 91.06%	[155]	
	Zhang et al., 2013	Stage I-IV EOC	87	Methylation-specific PCR	Sensitivity = 89.66% Specificity = 90.57%	[157]	
	Dvorská et al., 2019	Stage I-IV EOC	49	Pyrosequencing	Sensitivity = 98% Specificity = 56%	[171]	
	Su et al., 2009	Stage I-IV EOC	26	Methylation-specific PCR	Sensitivity = 73% Specificity = 75%	[172]	
	Melnikov et al., 2009	Stage I-IV EOC	33	Microarray mediated methylation assay	Sensitivity = 85% Specificity = 61%	[175]	
	Singh et al., 2020	Stage I-IV EOC	70	TaqMan based qPCR assay	Sensitivity = 89% Specificity = 100%	[176]	
	Cohen et al., 2018	Stage I-III EOC	54	Combined assays for genetic alterations and protein biomarkers (CancerSEEK)	Sensitivity = 98% Specificity = 99%	[177]	
	Exosomes	Schwich et al., 2019	Stage I-IV EOC	78	Nanoparticle tracking analysis, ELISA	100%	[187]

isolate CTCs from blood samples of 90 EOC patients. The authors did not find an association between the detection of CTCs and poor prognosis [18]. Using the CellSearch system, Poveda et al. found that among 216 ovarian cancer patients after primary debulking surgery and diagnosis of recurrence with failed first-line chemotherapy,

those with higher CTC levels, defined as ≥ 2 CTCs per 7.5 mL blood, had a 2.06-fold ($p=0.003$) higher overall mortality risk and 1.89-fold ($p=0.003$) higher risk of progression on doxorubicin treatment [183]. On the contrary, a multivariate analysis conducted by Marth et. al reported no statistically significant correlation between

the presence of CTCs in the bloodstream before surgery and PFS or OS. This study reported a mean overall survival of 25 and 28 months for patients with and without detected CTCs, respectively [18]. Similarly, Judson et al. analyzed pre-operative blood samples from 64 EOC patients and reported no significant difference in the OS ($p=0.96$) or PFS ($p=0.72$) between patients with and without detectable CTCs at a mean follow-up of 18.7 months [196]. Given this controversy, Huang et al. subsequently conducted a meta-analysis including 1285 patients from 2 clinical trials and 13 retrospective studies that demonstrated a significant association between the presence of CTCs before treatment with surgery or chemotherapy and both OS (HR=1.79, 95% CI:1.43–2.24, $p<0.00001$) and PFS (HR=1.59, 95%CI:1.30–1.94, $p<0.00001$) [197]. Other studies have suggested that the number of CTCs may be a potential prognostic factor for EOC patients, but the results are limited by small sample sizes and contradictory findings [21, 181–183, 198–201]. For example, some studies highlighted the prognostic role of CTCs, showing that the amount of pre-operative or post-adjuvant chemotherapy CTCs was associated with poor prognosis reflected in both PFS or OS [21, 181, 183, 199–201]. However, the results of these studies are inconsistent with other investigations that failed to find similar associations [22, 182, 198].

Currently, the prognostic value of other liquid biopsy components including cell-free miRNAs and exosomes lacks enough evidence for clinical applications. Several limiting factors in cell-free miRNAs studies, including the lack of standardized experimental procedures, varied normalization processes, and the inadequately powered sample sizes for statistical analysis have contributed to the controversy in this domain [110, 111, 186, 202, 203]. Several studies have supported the prognostic role of cell-free miRNAs such as miR-200 family, particularly miR-200a, miR-200b, and miR-200c [110, 111, 202, 203]. In another study with 40 EOC patients, Zhang et al. used Western blot analysis and enzyme-linked immunosorbent assay (ELISA) to analyze exosomal protein markers [186]. The study reported high levels of fibrinogen gamma chain (FGG) or lipopolysaccharide binding protein (LBP) mRNA expression were associated with worse prognosis and shorter PFS and OS for patients with EOC (FGG: OS HR=0.79, $P=0.001$ and PFS HR=0.77, $P<0.001$ for LBP: OS HR=0.81, $P=0.003$ and PFS HR=0.77, $P<0.001$) [186]. Since EVs contain several different tumour-derived components, EVs may be a promising all-in-one prognostic biomarker, providing information on the tumour and its microenvironment. However, the absence of a standardized approach for cell-free miRNA and EVs isolation and the small sample sizes of current studies limit the ability to draw definitive

conclusions and require future validation in larger cohorts. Table 2 summarizes the studies investigating the clinical application of liquid biopsy analytes as prognostic biomarkers in ovarian cancer.

Predicting and monitoring response to treatment

Although most ovarian cancer patients achieve complete remission after primary debulking surgery and adjuvant chemotherapy, up to 70% of patients develop recurrence due to chemoresistance. Intra-tumour heterogeneity has been proposed as the main cause of drug resistance and treatment failure in ovarian cancer [205]. Intra-tumour heterogeneity refers to the genomic variations within a lesion that arise from tumour cell evolution during the multistep tumorigenesis process. Clonal development from a single malignant cell into a functionally heterogeneous tumour mass is shaped by the tumour microenvironment and adaptation to various external selection pressures (e.g. evasion of apoptosis, self-sufficient cell proliferation, acquisition of replicative immortality). Subclones may evolve and expand in a sequentially linear fashion, or they may follow branched trajectories by continuing to diverge during their evolution trajectory (Fig. 5) [206, 207]. The molecular characterization of all ovarian cancer subclones is crucial for selecting appropriate targeted therapy and identifying acquired resistance in tumour cell clones over time. Liquid biopsy can potentially offer more comprehensive analysis of tumour heterogeneity and allow longitudinal monitoring of tumour evolution over the course of treatment.

The ability of ctDNA to reflect tumour heterogeneity is useful for predicting resistance to platinum-based chemotherapy, in addition to both primary and acquired resistance to PARPi. Approximately half of HGSOE patients have a Homologous Recombination Repair (HRR) deficiency leading to an impaired ability to repair double-stranded DNA breaks and increased sensitivity to the alkylating action of platinum-based chemotherapies that induce DNA damage [208]. *BRCA* mutated cells also depend on single-stranded DNA repair mechanisms involving Poly ADP-ribose Polymerase (PARP), which results in susceptibility to the synthetic lethality of PARPi [209]. Although ovarian tumours with pathogenic *BRCA1/2* variants have demonstrated increased sensitivity to platinum-based chemotherapy and PARPi, the majority will subsequently develop treatment resistance. Mechanisms leading to treatment resistance may be categorized broadly into two types. One of these is the small subclonal tumour cells that do not have the *BRCA1/2* mutations, and after starting treatment, become the main clone that does not respond to targeted treatment. The second mechanism is through acquired reversion mutations located close to the initial

Table 2 Liquid biopsy analytes and potential utility as prognostic biomarkers

Analyte	Author, Year	Tumour Subtype and Staging	Number of patients	Laboratory Technique	Prognostic Significance	Ref
CTCs	Zhang et al., 2018	Stage I-IV EOC	109	Immunomagnetic bead screening, RT-PCR	OS ($p=0.041$)	[181]
	Poveda et al., 2011	Stage I-IV EOC	216	CellSearch system and reagents	OS ($p=0.0017$) PFS ($p=0.00024$)	[183]
	Judson et al., 2003	Stage I-IV EOC	64	Immunocytochemical assay	NS	[196]
	Aktas et al., 2011	Stage I-IV EOC	122	AdnaTest BreastCancer, RT-PCR	OS ($p=0.0054$)	[199]
	Chebouti et al., 2017	Stage I-IV EOC	65	AdnaTest Ovarian Cancer, RT-PCR	OS ($p=0.0008$) PFS ($p=0.0293$)	[200]
	Kuhlmann et al., 2014	Stage I-IV EOC	143	Multiplex RT-PCR, immunomagnetic CTC enrichment	OS ($p=0.026$) PFS ($p=0.009$)	[16]
	Obermayr et al., 2013	Stage I-IV EOC	216	RT-qPCR, microarray analysis	OS ($p=0.001$) PFS ($p=0.001$)	[21]
ctDNA	Obermayr et al., 2017	Stage I-IV EOC	266	Density gradient centrifugation, immunostaining, FISH	OS ($p=0.007$) PFS ($p=0.008$)	[201]
	Giannopoulou et al., 2017	Stage I-IV EOC	59	Methylation-sensitive high-resolution melting analysis (MS-HRMA) assay	OS ($p=0.023$)	[153]
	Pereira et al., 2015	Stage I-IV EOC	10	Droplet digital PCR	OS ($p=0.0011$) PFS ($p=0.0194$)	[163]
	Parkinson et al., 2016	Stage I-IV EOC	40	Microfluidic digital PCR	TTP ($p=0.008$)	[164]
	Swisher et al., 2005	Stage I-IV EOC	137	DNA sequencing, PCR	OS ($p=0.02$)	[58]
	Giannopoulou et al., 2018	Stage I-IV EOC	53	Methylation-specific PCR	OS ($p=0.027$) PFS ($p=0.041$)	[170]
	No et al., 2012	Stage I-IV EOC	36	Copy number assay, qPCR	OS (HR = 33.6, 95% CI = 1.8–634.8) DFS (HR = 18.2, 95% CI = 2.0–170.0)	[178]
	Kuhlmann et al., 2012	Stage I-IV EOC	63	PCR-based fluorescence microsatellite analysis	OS ($p=0.030$)	[179]
	Pearl et al., 2014	Stage I-IV EOC	129	CAM-based identification platform	CTCs were better correlated with worse OS and PFS compared to CA125	[184]
	Pearl et al., 2015	Stage I-IV EOC	123	iCTC flow cytometry assay	CTCs more sensitive to progressive disease and relapse compared to CA125	[185]
	Minato et al., 2021	Stage I-IV EOC	11	Droplet digital PCR	Earlier recurrence detection compared to CA125	[195]
	Kim et al., 2019	Stage II-IV EOC	61	Droplet digital PCR	TTP ($p=0.038$)	[189]
	Paracchini et al., 2020	Stage III-IV EOC	46	Shallow whole-genome sequencing	PFS ($p=0.011$)	[204]
	cfRNA	Zuberi et al., 2015	Stage I-IV EOC	70	Trizol method	Disease progression ($p=0.001$)
Halvorsen et al., 2017		Stage I-IV EOC	207	TaqMan Low Density Arrays, RT-qPCR	OS ($p=0.012$) PFS ($p=0.006$)	[203]
Zhang et al., 2019		Stage I-IV EOC	40	liquid chromatography tandem mass spectrometry	OS ($p=0.0012$) PFS ($p=0.00038$)	[186]
Exosomes	Schwich et al., 2019	Stage I-IV EOC	78	Nanoparticle tracking analysis, ELISA	PFS ($p=0.029$)	[187]

OS Overall Survival, PFS Progression-Free Survival, NS Not Significant, TTP Time to Progression

loss-of-function variant that effectively restore functional protein production [210, 211].

Longitudinal monitoring of *BRCA* mutation evolution in HGSOE patients during PARPi therapy may be achieved with serial cfDNA sampling. Previous studies have demonstrated that both germline and somatic

BRCA reversion mutations can be detected in the cfDNA of patients with HGSOE [212, 213]. In the ARIEL2 trial, Lin et. al assessed the association between *BRCA* reversion mutations and clinical efficacy of adjuvant PARPi treatment. This study included 112 HGSOE patients with germline or somatic *BRCA1/2* mutations and used




Fig. 5 The utility of liquid biopsy during different stages of tumour progression. The molecular profile of the primary tumour changes as cancer progresses. New mutations and treatments can lead to intra-tumour heterogeneity. Furthermore, heterogeneity causes drug resistance and treatment failure. Liquid biopsy can aid in the detection of primary ovarian tumours (A). The prognosis of EOC patients can potentially be determined by liquid biopsy (B). Likewise, this technique can help with the detection of residual disease after primary debulking surgery and contribute to the detection of EOC recurrence (C). Physicians can potentially use liquid biopsy to uncover the molecular profile of the tumor and select the correct therapy for each patient (D). Liquid biopsy can also reflect tumour heterogeneity and predict resistance to platinum-based chemotherapy in addition to both primary and acquired resistance to PARPi (E)

NGS to analyze plasma cfDNA collected prior to PARPi treatment with rucaparib after disease progression on platinum-based chemotherapy. The researchers found that the absence of reverse *BRCA* mutations in pre-treatment cfDNA was associated with a longer PFS on rucaparib with a median PFS of 9.0 months, compared to 1.8 months in patients with detectable *BRCA* reversion mutations in their cfDNA (HR 0.12; $p < 0.0001$). In addition, this study also sequenced 78 post-progression cfDNA samples to examine acquired resistance and identified an additional 8 patients with novel *BRCA* reversion mutations not initially found in pre-treatment cfDNA, suggesting the ability of cfDNA to monitor dynamic changes in *BRCA* mutational status over time [212]. Other studies have reported a similar association between detection of *BRCA1/2* reversion mutations in plasma ctDNA and resistance to adjuvant platinum and PARPi therapy (Table 3) [213, 214]. Christie et al. conducted a prospective study with 30 HGSOE patients with a germline *BRCA1/2* mutation to determine whether cfDNA analysis could predict chemotherapy response

in both the neoadjuvant and adjuvant setting. In this study, paired tumour and plasma samples were collected for two cohorts of patients: one cohort comprised 14 patients receiving treatment prior to primary debulking surgery and the second cohort included 16 patients receiving treatment after recurrence with previous adjuvant platinum-based chemotherapy. The researchers used targeted NGS to first screen tumour samples for germline *BRCA1/2* mutation or reversion status before analyzing cfDNA. This study only detected *BRCA1/2* reversion mutations in tumour samples of 31.3% (5 of 16) patients in the second cohort with recurrent disease, among which 18.8% (3 of 5 patients) also had detectable reversions in cfDNA. Clinically, all cases with detectable reversions in cfDNA subsequently became resistant to platinum or PARPi therapy. Routine monitoring through liquid biopsy may therefore allow for earlier detection of resistance and selection of more personalized combination therapies (i.e. alternative chemotherapies, targeted therapies or immunotherapy) targeting different oncogenic drivers to reduce the risk of resistance.

Table 3 Clinical utility of ctDNA as liquid biopsy for predicting and monitoring response to treatment

Author, Year	Tumour Classification	Sample Size	Laboratory Methodology	Detected Abnormality	Treatment Protocol	Clinical Application	Ref
Gifford et al., 2004	Stage Ic-IV EOC	138	Microsatellite PCR	hMLH1 methylation	Paclitaxel/docetaxel + carboplatin	Response monitoring	[215]
Swisher et al., 2005	Stage I-IV EOC	137	DNA sequencing	p53 mutation	Taxane + platinum agent	Response monitoring	[58]
Capizzi et al., 2008	Stage III-IV EOC	22	RT-PCR	Serum level	Carboplatin + paclitaxel or carboplatin only	Response monitoring	[216]
Kamat et al., 2010	Stage I-IV EOC	164	RT-PCR	Beta-globin	Platinum agent	Response monitoring	[217]
Wimberger et al., 2011	Stage Ib-IV EOC	62	Fluorescence	Fluorimetry	Carboplatin + paclitaxel	Response monitoring	[218]
Forsheew et al., 2012	HGSOC	38	TAm-Seq, dPCR	<i>TP53, PTEN, BRAF, KRAS, EGFR, PIK3CA</i> mutations	Carboplatin + paclitaxel or epirubicin + cisplatin + capecitabine	Response monitoring	[162]
Murtaza et al., 2013	Stage III-IV	3	NGS, qPCR	<i>RB1, ZEB2, BUB1, CES4A, MTOR, PARP8</i> mutations	Cisplatin, paclitaxel or carboplatin + paclitaxel	Response monitoring	[168]
Choudhuri et al., 2014	Stage IIb/c	100	RT-PCR	Serum level	Carboplatin + paclitaxel	Response monitoring	[219]
Martignetti et al., 2014	Stage IIc Serous Papillary	1	RT-PCR	FGFR2 fusion transcript	Carboplatin + paclitaxel (total 5 lines of treatment)	Response monitoring	[220]
Pereira et al., 2015	Stage I-IV Serous	22	WES, ddPCR, TGS	<i>TP53, PTEN, PIK3CA, MET, KRAS, FBXW7, BRAF</i> mutations	Platinum + taxane agent	Response monitoring	[163]
Piskorz et al., 2016	HGSOC	18	NGS	<i>TP53</i> mutation	Platinum agent	Response monitoring	[91]
Parkinson et al., 2016	Relapsed HGSOC	40	Digital PCR	<i>TP53</i> mutation	Heterogeneous standard of care treatment	Response monitoring	[164]
Flanagan et al., 2017	Relapsed Stage I-IV Serous	247	NGS	Methylation at CpG sites	Platinum agent	Response monitoring	[221]
Widschwendter et al., 2017	Stage I-IV HGSOC or Clear Cell	151	TUC-BS & RRBS	<i>COL23A1, C2CD4D</i> and <i>WNT6</i> candidate markers	Carboplatin + paclitaxel or carboplatin only	Response monitoring	[161]
Ratajska et al., 2017	Stage I-IV	121	NGS	<i>BRCA1/2</i> mutations	PARPi	Predict eligibility for PARPi	[222]
Christie et al., 2017	Stage I-IV HGSOC	30	NGS	<i>BRCA</i> reversion mutation	Platinum-based agent and/or PARPi	Predict treatment response	[213]
Weigelt et al., 2017	Stage III-IV	19	NGS	<i>BRCA</i> reversion mutation	Platinum-based agent ± taxane agent	Response monitoring	[214]
Giannopoulou et al., 2018	Stage I-IV HGSOC	50	RT-MSP	ESR1	Carboplatin + paclitaxel	Response monitoring	[153]
Du et al., 2018	Recurrent Stage II-III Serous	21	NGS	<i>TP53, BRCA1, NOTCH2, DNMT3A</i> mutations and CNVs	Platinum-based agent	Response monitoring	[165]
Morikawa et al., 2018	Stage I-IV Clear Cell	29	ddPCR	<i>KRAS, PIK3CA</i>	Carboplatin + paclitaxel ± docetaxel/ carboplatin/gemcitabine/bevacizumab/ CPT-11/irinotecan	Response monitoring	[223]
Arend et al., 2018	Stage III-IV HGSOC	14	NGS	50 gene Ion Torrent panel	Platinum + taxane agent	Response monitoring	[188]
Lin et al., 2019	High Grade Serous and Endometrioid	97	NGS	<i>BRCA</i> reversion mutation, <i>TP53</i>	PARPi (rucaparib)	Predict primary and acquired resistance	[212]
Kim et al., 2018	Stage II-IV HGSOC	102	Sanger sequencing/ Digital PCR	<i>TP53</i> mutation	Carboplatin + paclitaxel	Response monitoring	[189]
Oikonen et al., 2019	HGSOC	12	NGS	<i>ERBB2</i> amplification	Platinum + taxane agent ± trastuzumab	Response monitoring	[224]
Iwahashi et al., 2019	Stage I-IV HGSOC, Mucinous, Endometrioid	4	CAPP-seq	<i>TP53, APC, BRCA1</i> and <i>KRAS</i> mutations	Carboplatin + paclitaxel	Response monitoring	[225]

Table 3 (continued)

Author, Year	Tumour Classification	Sample Size	Laboratory Methodology	Detected Abnormality	Treatment Protocol	Clinical Application	Ref
Noguchi et al., 2020	Stage III-IV HGSOc	10	CAPP-seq	gene mutation profiles, blood tumor mutation burden	Carboplatin + paclitaxel ± bevacizumab	Response monitoring	[226]
Han et al., 2020	Stage III-IV EOC	10	NGS	88 genes panel (Axen Cancer Panel 1)	Standard chemotherapy	Response monitoring	[227]
Alves et al. 2020	Stage I-IV Serous, Clear Cell, Mucinous	11	qPCR	Level	Carboplatin + paclitaxel, gemcitabine, doxorubicin + bevacizumab or rucaparib (PARPi)	Response monitoring	[228]

Other somatic mutations seen more frequently in ovarian cancer may be used for monitoring response to treatment. As the main driver of clonal pathogenic lesions, *TP53* mutations are in nearly all primary ovarian tumour cells, synchronous tumours, and metachronous lesions. Detection of *TP53* mutations was therefore hypothesized to be a suitable biomarker for disease monitoring. Since the feasibility of sequencing cfDNA fragments to detect tumour-associated *TP53* mutation was first reported more than 15 years ago, studies have demonstrated that *TP53* mutation detection can evaluate tumour burden, predict time to progression (TTP) and detect tumour recurrence [58, 91, 162–165, 189, 229, 230]. Similarly, another study that used whole-exome sequencing of plasma cfDNA to serially quantify allele fractions (AF) in plasma identified an increased representation of mutant alleles associated with the development of treatment resistance in three ovarian cancer patients. The researchers found that increased mutant AF of *RB1* and *ZEB2* was associated with cisplatin resistance, while *MTOR*, *CES4A* and *BUB1* mutations were associated with paclitaxel and carboplatin resistance, and *PARP8* mutation was associated with liposomal doxorubicin resistance [168].

In terms of other mutations, Forshe et al. reported the emergence of a de novo EGFR tyrosine kinase mutation in an HGSOc patient at disease relapse that was not present 15 months earlier in the initial tumour sample [162]. This patient was identified to be eligible for treatment with gefitinib or erlotinib, however, the treatment efficacy and final clinical outcome were not reported. The study authors used tagged-amplicon deep sequencing (TAm-Seq) and screened 5995 genomic bases for low-frequency mutations to identify cancer mutations present in cfDNA at allele frequencies as low as 2%. More recently, Oikkonen et al. conducted a prospective cohort study with 78 cfDNA samples collected from 12 HGSOc patients collected before, during and after platinum-based chemotherapy, and detected clinically actionable mutations in 7 (58%) of patients. In one patient with

ERBB2 amplification detected in ctDNA following the development of resistance to platinum chemotherapy, treatment was changed to trastuzumab with reduced dose carboplatin and dose-dense paclitaxel, with significant tumour shrinkage and complete normalization of CA-125 achieved [224]. Table 3 summarizes the studies investigating the clinical application of ctDNA for predicting and monitoring response to treatment in ovarian cancer.

Conclusions and future directions

There is emerging evidence supporting the potential of liquid biopsy to enhance ovarian cancer management with the goal of improving survival. In the last decade, advances made in molecular analysis technologies have allowed for increased clinical applications of liquid biopsy in the diagnosis, prognosis, and prediction of response to treatment in ovarian cancer. The advantages over traditional biopsies include the ability for earlier detection of cancer and identification of microscopic minimal residual disease following primary debulking surgery, which are important considerations in ovarian cancer due to the possibility for earlier intervention and improved survival outcomes. Liquid biopsy can also capture the heterogeneity of ovarian tumours more comprehensively compared to conventional tissue biopsy. The non-invasiveness and feasibility of liquid biopsy allow for serial sampling and longitudinal monitoring to identify treatment resistance with tumour evolution over time and guide the selection of personalized therapy.

Currently, several challenges remain to be addressed prior to more routine utilization of liquid biopsy in ovarian cancer. For example, cfDNA analysis has limited sensitivity and specificity for early-stage ovarian cancer. Consequently, genetic mutations detected in the cfDNA or ctDNA should only be used to guide clinical decision-making in conjunction with other biomarkers and imaging techniques to improve the overall sensitivity and specificity. In addition, given the low proportion

of ctDNA in cfDNA, optimization of current isolation strategies and improved sensitivity of analysis techniques are required to enhance the extraction yield and enable ctDNA detection at low allele frequencies. Another limitation is the current lack of reproducibility of liquid biopsy assays due to the lack of standardization across different laboratory workflows. Future studies should estimate the technical robustness and reproducibility of proposed biomarkers within and between laboratories by implementing a standardized procedure. Further studies examining the specific mechanisms of release, tissue of origin and biological significance are also required for most liquid biopsy components prior to clinical use.

Another challenge is to elucidate the multifactorial processes implicated in the development of chemoresistance that contributes to the high mortality rates in ovarian cancer. During treatment, regular monitoring with liquid biopsy can elucidate drug resistance acquired from genetic alterations, which may be present but undetectable with conventional approaches. The implications of oncogene expression on cancer drug resistance remain poorly understood, although there have been over 25 oncogenes including *KRAS*, *ERBB2*, *PIK3CA*, *AKT* hypothesized to contribute to drug resistance in ovarian cancer through various signalling pathways [215, 216, 224]. Genomic-based drug response prediction may offer a new horizon in ovarian cancer to improve clinical management. However, previous studies on drug resistance have been limited to small samples from certain ovarian cancer cell lines and have focused largely on ctDNA analysis [231–233]. In the future, more studies are required to examine the utility of liquid biopsy in predicting treatment response among different ovarian cancer subtypes and to compare the efficacy of the various liquid biopsy analytes. Further efforts to standardize analysis platforms and incorporate liquid biopsies as a companion biomarker in large-scale drug trials are also warranted.

In conclusion, liquid biopsy has emerged as a promising alternative to traditional tissue sampling methods for its potential utility in the earlier detection and management of ovarian cancer. However, current evidence suggests that liquid biopsy may be best used as a second-line or complementary diagnostic tool rather than the sole biomarker in deciding clinical management. To date, most studies evaluating liquid biopsy techniques are limited by small sample sizes and larger, higher-quality studies are required to provide more rigorous evidence prior to their routine clinical application.

Acknowledgements

Not applicable.

Authors' contributions

MA and JZ designed the outline of the article. JZ and PC wrote the initial manuscript draft, and MA, JZ and PC revised and expanded the manuscript. All authors have seen and approved the final manuscript.

Funding

The authors hereby declare that they did not receive any funding or financial support for preparation of this manuscript. Dr. Akbari's lab is supported by grant funding from Canadian Institute for Health Research and Peter Gilgan Foundation.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Authors consent the publication of this manuscript by the *Molecular Cancer* journal.

Competing interests

The authors declared that they have no competing interests.

Author details

¹Women's College Research Institute, Women's College Hospital, University of Toronto, 76 Grenville St, Toronto, ON M5S 1B2, Canada. ²Department of Medicine, McMaster University, Hamilton, ON, Canada. ³Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ⁴Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Received: 4 January 2022 Accepted: 27 April 2022

Published online: 11 May 2022

References

- Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. *Int J Cancer*. 2017;140(11):2451–60. <https://doi.org/10.1002/ijc.30676>.
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–86. <https://doi.org/10.1002/ijc.29210>.
- Köbel M, Rahimi K, Rambau PF, et al. An immunohistochemical algorithm for ovarian carcinoma typing. *Int J Gynecol Pathol*. 2016;35(5):430–41. <https://doi.org/10.1097/PGP.0000000000000274>.
- Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. *Hum Pathol*. 2011;42(7):918–31. <https://doi.org/10.1016/j.humpath.2011.03.003>.
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011;474(7353):609–15. <https://doi.org/10.1038/nature10166>.
- González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*. 2019;381(25):2391–402. <https://doi.org/10.1056/NEJMoa1910962>.
- Liu JF, Matulonis UA. What is the place of PARP Inhibitors in ovarian cancer treatment? *Curr Oncol Rep*. 2016;18(5):29. <https://doi.org/10.1007/s11912-016-0515-z>.
- Mirza MR, Monk BJ, Herrstedt J, et al. niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med*. 2016;375(22):2154–64. <https://doi.org/10.1056/NEJMoa1611310>.
- Hennessy BT, Coleman RL, Markman M. Ovarian cancer. *Lancet*. 2009;374(9698):1371–82. [https://doi.org/10.1016/S0140-6736\(09\)61338-6](https://doi.org/10.1016/S0140-6736(09)61338-6).
- Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. *Am J Obstet Gynecol*. 2011;205(5):480.e1–8. <https://doi.org/10.1016/j.ajog.2011.06.049>.

11. Morgan RJ, Armstrong DK, Alvarez RD, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016;14(9):1134–63. <https://doi.org/10.6004/jnccn.2016.0122>.
12. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet*. 2018;143(Suppl 2):59–78. <https://doi.org/10.1002/ijgo.12614>.
13. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet*. 2016;387(10022):945–56. [https://doi.org/10.1016/S0140-6736\(15\)01224-6](https://doi.org/10.1016/S0140-6736(15)01224-6).
14. Yang J, Ma J, Jin Y, et al. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. *Sci Rep*. 2021;11(1):6540. <https://doi.org/10.1038/s41598-021-86122-4>.
15. Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. *Gynecol Oncol*. 2013;131(2):352–6. <https://doi.org/10.1016/j.ygyno.2013.08.006>.
16. Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. *Clin Chem*. 2014;60(10):1282–9. <https://doi.org/10.1373/clinchem.2014.224808>.
17. Nie L, Li F, Huang X, et al. Folic Acid Targeting for Efficient Isolation and Detection of Ovarian Cancer CTCs from Human Whole Blood Based on Two-Step Binding Strategy. *ACS Appl Mater Interfaces*. 2018;10(16):14055–62. <https://doi.org/10.1021/acsami.8b02583>.
18. Marth C, Kisc J, Kaern J, TROPÉ C, Fodstad Ø. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. *Cancer*. 2002;94(3):707–12. <https://doi.org/10.1002/cncr.10250>.
19. Zaborowski MP, Stefens-Stawna P, Osztynowicz K, et al. Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy. *Cancer Immunol Immunother*. 2021;70(5):1277–89. <https://doi.org/10.1007/s00262-020-02750-1>.
20. Obermayr E, Reiner A, Brandt B, et al. The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. *Cancers (Basel)*. 2021;13(11):2613. <https://doi.org/10.3390/cancers13112613>.
21. Obermayr E, Castillo-Tong DC, Pils D, et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – a study of the OVCAD consortium. *Gynecol Oncol*. 2013;128(1):15–21. <https://doi.org/10.1016/j.ygyno.2012.09.021>.
22. Kolostova K, Pinkas M, Jakabova A, et al. Molecular characterization of circulating tumor cells in ovarian cancer. *Am J Cancer Res*. 2016;6(5):973–80.
23. Obermayr E, Sanchez-Cabo F, Tea MKM, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. *BMC Cancer*. 2010;10:666. <https://doi.org/10.1186/1471-2407-10-666>.
24. Ried K, Eng P, Sali A. Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study. *Asian Pac J Cancer Prev*. 2017;18(8):2275–85. <https://doi.org/10.22034/APJCP.2017.18.8.2275>.
25. Kim M, Suh DH, Choi JY, et al. Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study. *Medicine (Baltimore)*. 2019;98(20):e15354. <https://doi.org/10.1097/MD.00000000000015354>.
26. Rao Q, Zhang Q, Zheng C, et al. Detection of circulating tumour cells in patients with epithelial ovarian cancer by a microfluidic system. *Int J Clin Exp Pathol*. 2017;10(9):9599–606.
27. Obermayr E, Maritschnegg E, Agreiter C, et al. Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. *Oncotarget*. 2018;9(1):812–23. <https://doi.org/10.18632/oncotarget.22549>.
28. Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. *Gynecol Oncol*. 2017;145(2):361–5. <https://doi.org/10.1016/j.ygyno.2017.02.042>.
29. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. *Gynecol Oncol*. 2009;112(1):185–91. <https://doi.org/10.1016/j.ygyno.2008.09.021>.
30. Mishima Y, Paiva B, Shi J, et al. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. *Cell Rep*. 2017;19(1):218–24. <https://doi.org/10.1016/j.celrep.2017.03.025>.
31. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. *Cell*. 2004;118(3):277–9. <https://doi.org/10.1016/j.cell.2004.07.011>.
32. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. *Cell*. 2012;148(1–2):349–61. <https://doi.org/10.1016/j.cell.2011.11.025>.
33. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. *Cell*. 2009;139(7):1315–26. <https://doi.org/10.1016/j.cell.2009.11.025>.
34. Young R, Pailler E, Billiot F, et al. Circulating tumor cells in lung cancer. *Acta Cytol*. 2012;56(6):655–60. <https://doi.org/10.1159/000345182>.
35. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. *J Cell Biol*. 2011;192(3):373–82. <https://doi.org/10.1083/jcb.201010021>.
36. Nelson NJ. Circulating tumor cells: will they be clinically useful? *J Natl Cancer Inst*. 2010;102(3):146–8. <https://doi.org/10.1093/jnci/djq016>.
37. Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov*. 2016;6(5):479–91. <https://doi.org/10.1158/2159-8290.CD-15-1483>.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–74. <https://doi.org/10.1016/j.cell.2011.02.013>.
39. Fidler IJ. Cancer biology is the foundation for therapy. *Cancer Biol Ther*. 2005;4(9):1036–9. <https://doi.org/10.4161/cbt.4.9.2111>.
40. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer*. 2009;9(4):274–84. <https://doi.org/10.1038/nrc2622>.
41. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252–64. <https://doi.org/10.1038/nrc3239>.
42. Zhong X, Zhang H, Zhu Y, et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. *Mol Cancer*. 2020;19(1):15. <https://doi.org/10.1186/s12943-020-1141-9>.
43. Jaiswal S, Jamieson CHM, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell*. 2009;138(2):271–85. <https://doi.org/10.1016/j.cell.2009.05.046>.
44. Agerbæk MØ, Bang-Christensen SR, Yang MH, et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. *Nat Commun*. 2018;9(1):3279. <https://doi.org/10.1038/s41467-018-05793-2>.
45. Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? *Cancer Lett*. 2020;468:59–71. <https://doi.org/10.1016/j.canlet.2019.10.014>.
46. Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, Kim JS. One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. *Int J Nanomedicine*. 2013;8:2247–57. <https://doi.org/10.2147/IJN.S45059>.
47. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol*. 2013;10(8):472–84. <https://doi.org/10.1038/nrclinonc.2013.110>.
48. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol*. 2017;14(9):531–48. <https://doi.org/10.1038/nrclinonc.2017.14>.
49. Lo YM, Patel P, Wainscoat JS, Sampietro M, Gillmer MD, Fleming KA. Prenatal sex determination by DNA amplification from maternal peripheral blood. *Lancet*. 1989;2(8676):1363–5. [https://doi.org/10.1016/S0140-6736\(89\)91969-7](https://doi.org/10.1016/S0140-6736(89)91969-7).
50. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. *Cancer Discov*. 2014;4(6):650–61. <https://doi.org/10.1158/2159-8290.CD-13-1014>.
51. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. *Proc Natl Acad Sci U S A*. 2005;102(45):16368–73. <https://doi.org/10.1073/pnas.0507904102>.
52. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res*. 2001;61(4):1659–65.

53. Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. *Expert Opin Biol Ther*. 2012;12(Suppl 1):S209-215. <https://doi.org/10.1517/14712598.2012.688023>.
54. Mari R, Mamessier E, Lambaudie E, et al. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. *Cancers (Basel)*. 2019;11(6):E774. <https://doi.org/10.3390/cancers11060774>.
55. Barbosa A, Peixoto A, Pinto P, Pinheiro M, Teixeira MR. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. *Expert Rev Mol Med*. 2018;20:e6. <https://doi.org/10.1017/erm.2018.5>.
56. Li B, Pu K, Ge L, Wu X. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis. *Gene*. 2019;714: 143993. <https://doi.org/10.1016/j.gene.2019.143993>.
57. Salvi S, Gurioli G, De Giorgi U, et al. Cell-free DNA as a diagnostic marker for cancer: current insights. *Onco Targets Ther*. 2016;9:6549-59. <https://doi.org/10.2147/OTT.S100901>.
58. Swisher EM, Wollan M, Mahtani SM, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. *Am J Obstet Gynecol*. 2005;193(3 Pt 1):662-7. <https://doi.org/10.1016/j.ajog.2005.01.054>.
59. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. *Cell*. 2016;164(1-2):57-68. <https://doi.org/10.1016/j.cell.2015.11.050>.
60. Zhang R, Nakahira K, Guo X, Choi AMK, Gu Z. Very Short Mitochondrial DNA Fragments and Heteroplasmy in Human Plasma. *Sci Rep*. 2016;6:36097. <https://doi.org/10.1038/srep36097>.
61. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. *Sci Transl Med*. 2018;10(466):eaat4921. <https://doi.org/10.1126/scitranslmed.aat4921>.
62. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. *Eur J Cancer Clin Oncol*. 1987;23(6):707-12. [https://doi.org/10.1016/0277-5379\(87\)90266-5](https://doi.org/10.1016/0277-5379(87)90266-5).
63. Jiang P, Chan CWM, Chan KCA, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. *Proc Natl Acad Sci U S A*. 2015;112(11):E1317-1325. <https://doi.org/10.1073/pnas.1500076112>.
64. Muhanna N, Di Grappa MA, Chan HHL, et al. Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer. *Sci Rep*. 2017;7(1):16723. <https://doi.org/10.1038/s41598-017-17079-6>.
65. Beyer C, Stearns NA, Giessi A, Distler JHW, Schett G, Pisetsky DS. The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. *Innate Immun*. 2012;18(5):727-37. <https://doi.org/10.1177/1753425912437981>.
66. Beyer C, Pisetsky DS. Modeling nuclear molecule release during in vitro cell death. *Autoimmunity*. 2013;46(5):298-301. <https://doi.org/10.3109/08916934.2012.750297>.
67. Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Koike I, Inoue T. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. *Cancer Sci*. 2009;100(2):303-9. <https://doi.org/10.1111/j.1349-7006.2008.01021.x>.
68. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res*. 1977;37(3):646-50.
69. Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev*. 2016;35(3):347-76. <https://doi.org/10.1007/s10555-016-9629-x>.
70. Bronkhorst AJ, Wentzel JF, Aucamp J, van Dyk E, du Plessis L, Pretorius PJ. Characterization of the cell-free DNA released by cultured cancer cells. *Biochim Biophys Acta*. 2016;1863(1):157-65. <https://doi.org/10.1016/j.bbamcr.2015.10.022>.
71. Roy S, Coldren C, Karunamurthy A, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the association for molecular pathology and the College of American Pathologists. *J Mol Diagn*. 2018;20(1):4-27. <https://doi.org/10.1016/j.jmoldx.2017.11.003>.
72. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. *Immunol Rev*. 2011;243(1):206-14. <https://doi.org/10.1111/j.1600-065X.2011.01044.x>.
73. Kemp MG, Reardon JT, Lindsey-Boltz LA, Sancar A. Mechanism of release and fate of excised oligonucleotides during nucleotide excision repair. *J Biol Chem*. 2012;287(27):22889-99. <https://doi.org/10.1074/jbc.M112.374447>.
74. Peters DL, Pretorius PJ. Origin, translocation and destination of extracellular occurring DNA—a new paradigm in genetic behaviour. *Clin Chim Acta*. 2011;412(11-12):806-11. <https://doi.org/10.1016/j.cca.2011.01.026>.
75. Underhill HR, Kitzman JO, Hellwig S, et al. Fragment Length of Circulating Tumor DNA. *PLoS Genet*. 2016;12(7):e1006162. <https://doi.org/10.1371/journal.pgen.1006162>.
76. Mouliere F, Piskorz AM, Chandrananda D, Moore E, Morris J, Smith CG, et al. Selecting short DNA fragments in plasma improves detection of circulating tumour DNA. *bioRxiv*. 2017;1:34437. <https://doi.org/10.1101/134437>.
77. Huang A, Zhang X, Zhou SL, et al. Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma. *J Cancer*. 2016;7(13):1798-803. <https://doi.org/10.7150/jca.15618>.
78. Chen H, Sun L-yu, Zheng H qun, Zhang Q fan, Jin X ming. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. *Pathology*. 2012;44(4):318-24. <https://doi.org/10.1097/PAT.0b013e328353a24c>.
79. Gang F, Guorong L, An Z, Anne GP, Christian G, Jacques T. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. *Urology*. 2010;75(2):262-5. <https://doi.org/10.1016/j.urology.2009.06.048>.
80. Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. *Ann Surg Oncol*. 2011;18(9):2461-8. <https://doi.org/10.1245/s10434-011-1638-y>.
81. Leung F, Kulasingam V, Diamandis EP, et al. Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? *Clin Chem*. 2016;62(8):1054-60. <https://doi.org/10.1373/clinchem.2016.260331>.
82. Stephan F, Marsman G, Bakker LM, et al. Cooperation of factor VII-activating protease and serum DNase I in the release of nucleosomes from necrotic cells. *Arthritis Rheumatol*. 2014;66(3):686-93. <https://doi.org/10.1002/art.38265>.
83. Martin M, Leffler J, Smoląg KI, et al. Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes. *Cell Death Differ*. 2016;23(5):903-11. <https://doi.org/10.1038/cdd.2015.164>.
84. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. *Am J Hum Genet*. 1999;64(1):218-24. <https://doi.org/10.1086/302205>.
85. Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. *Nucleic Acids Res*. 2010;38(18):6159-75. <https://doi.org/10.1093/nar/gkq421>.
86. García Moreira V, de la Cera MT, Gago González E, Prieto García B, Alvarez Menéndez FV. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. *Clin Chem Lab Med*. 2006;44(12):1410-5. <https://doi.org/10.1515/CCLM.2006.252>.
87. Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. *J Immunol*. 1996;156(3):1151-6.
88. Yu SCY, Lee SWY, Jiang P, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. *Clin Chem*. 2013;59(8):1228-37. <https://doi.org/10.1373/clinchem.2013.203679>.
89. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. *Sci Transl Med*. 2017;9(403):eaan2415. <https://doi.org/10.1126/scitranslmed.aan2415>.
90. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014;6(224):224ra24. <https://doi.org/10.1126/scitranslmed.3007094>.
91. Piskorz A, Lin KK, Morris JA, et al. Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial. *J Clin Oncol*. 2016;34(15):5549-5549.
92. Žilović D, Čiurlienė R, Sabaliauskaitė R, Jarmalaitė S. Future Screening Prospects for Ovarian Cancer. *Cancers (Basel)*. 2021;13(15):3840. <https://doi.org/10.3390/cancers13153840>.
93. Schmitt MW, Fox EJ, Prindle MJ, et al. Sequencing small genomic targets with high efficiency and extreme accuracy. *Nat Methods*. 2015;12(5):423-5. <https://doi.org/10.1038/nmeth.3351>.
94. Ahn EH, Hirohata K, Kohn BF, Fox EJ, Chang CC, Loeb LA. Detection of Ultra-Rare Mitochondrial Mutations in Breast Stem Cells by Duplex

- Sequencing. *PLoS ONE*. 2015;10(8): e0136216. <https://doi.org/10.1371/journal.pone.0136216>.
95. Kinde I, Bettgowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. *Sci Transl Med*. 2013;5(167):167ra4. <https://doi.org/10.1126/scitranslmed.3004952>.
 96. Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. *Sci Transl Med*. 2018;10(433):eaap8793. <https://doi.org/10.1126/scitranslmed.aap8793>.
 97. Maritschnegg E, Wang Y, Pecha N, et al. Lavage of the uterine cavity for molecular detection of müllerian duct carcinomas: a proof-of-concept study. *J Clin Oncol*. 2015;33(36):4293–300. <https://doi.org/10.1200/JCO.2015.61.3083>.
 98. Erickson BK, Kinde I, Dobbin ZC, et al. Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. *Obstet Gynecol*. 2014;124(5):881–5. <https://doi.org/10.1097/AOG.0000000000000484>.
 99. Naz S, Hashmi AA, Ali R, et al. Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters. *World J Surg Oncol*. 2015;13:315. <https://doi.org/10.1186/s12957-015-0732-1>.
 100. Zuna RE, Behrens A. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. *J Natl Cancer Inst*. 1996;88(14):980–7. <https://doi.org/10.1093/jnci/88.14.980>.
 101. Jia MM, Deng J, Cheng XL, et al. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. *Oncotarget*. 2017;8(6):9660–71. <https://doi.org/10.18632/oncotarget.14173>.
 102. Anker P, Lyautey J, Lederer C, Stroun M. Circulating nucleic acids in plasma or serum. *Clin Chim Acta*. 2001;313(1–2):143–6. [https://doi.org/10.1016/s0009-8981\(01\)00666-0](https://doi.org/10.1016/s0009-8981(01)00666-0).
 103. Dwivedi SKD, Rao G, Dey A, Mukherjee P, Wren JD, Bhattacharya R. Small Non-Coding-RNA in Gynecological Malignancies. *Cancers (Basel)*. 2021;13(5):1085. <https://doi.org/10.3390/cancers13051085>.
 104. Koprski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. *Clin Cancer Res*. 1999;5(8):1961–5.
 105. Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. *Nat Med*. 2011;17(12):1627–35. <https://doi.org/10.1038/nm.2512>.
 106. Shen W, Song M, Liu J, et al. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. *PLoS ONE*. 2014;9(1): e86871. <https://doi.org/10.1371/journal.pone.0086871>.
 107. Li N, Yang L, Wang H, et al. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. *PLoS ONE*. 2015;10(6): e0128886. <https://doi.org/10.1371/journal.pone.0128886>.
 108. Wang L, Zhao F, Xiao Z, Yao L. Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA. *Cancer Cell Int*. 2019;19:281. <https://doi.org/10.1186/s12935-019-0990-z>.
 109. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol*. 2008;110(1):13–21. <https://doi.org/10.1016/j.ygyno.2008.04.033>.
 110. Gao YC, Wu J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. *Tumour Biol*. 2015;36(6):4843–50. <https://doi.org/10.1007/s13277-015-3138-3>.
 111. Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. *Oncotarget*. 2016;7(13):16923–35. <https://doi.org/10.18632/oncotarget.7850>.
 112. Kim S, Choi MC, Jeong JY, et al. Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. *J Cancer*. 2019;10(9):1958–67. <https://doi.org/10.7150/jca.30231>.
 113. Matsuzaki J, Ochiya T. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. *Int J Clin Oncol*. 2017;22(3):413–20. <https://doi.org/10.1007/s10147-017-1104-3>.
 114. Elias KM, Fendler W, Stawiski K, et al. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. *Elife*. 2017;6: e28932. <https://doi.org/10.7554/eLife.28932>.
 115. Yokoi A, Yoshioka Y, Hirakawa A, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. *Oncotarget*. 2017;8(52):89811–23. <https://doi.org/10.18632/oncotarget.20688>.
 116. Yokoi A, Matsuzaki J, Yamamoto Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening. *Nat Commun*. 2018;9(1):4319. <https://doi.org/10.1038/s41467-018-06434-4>.
 117. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA*. 2013;19(2):141–57.
 118. Lasda E, Parker R. Circular RNAs: diversity of form and function. *RNA*. 2014;20(12):1829–42.
 119. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. *Nature Biotechnol*. 2014;32(5):453–61.
 120. Ahmed I, Karedath T, Andrews SS, et al. Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. *Oncotarget*. 2016;7(24):36322–81.
 121. Hu Y, Zhu Y, Zhang W, Lang J, Ning L. Utility of plasma circBNC2 as a diagnostic biomarker in epithelial ovarian cancer. *Onco Targets Ther*. 2019;12:9715–23.
 122. Meryet-Figuière M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, Denoyelle C. An overview of long non-coding RNAs in ovarian cancers. *Oncotarget*. 2016;7:44719–34. <https://doi.org/10.18632/oncotarget.8089>.
 123. Hu X, Feng Y, Zhang D, et al. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. *Canc Cell*. 2014;26:344–57. <https://doi.org/10.1016/j.ccr.2014.07.009>.
 124. Zhao L, Ji G, Le X, Wang C, et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. *Canc Res*. 2017;77:1369–82. <https://doi.org/10.1158/0008-5472.CAN-16-1615>.
 125. Zhang S, Leng T, Zhang Q, Zhao Q, Nie X, Yang L. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CAS2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway. *Biomed Pharmacother*. 2018;102:302–8. <https://doi.org/10.1016/j.biopha.2018.03.071>.
 126. Shang A, Wang W, Gu C, Chen C, Zeng B, Yang Y, Ji P, Sun J, Wu J, Lu W, Sun Z, Li D. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. *J Exp Clin Cancer Res*. 2019;38:411. <https://doi.org/10.1186/s13046-019-1394-6>.
 127. Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long noncoding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. *Mol Carcinog*. 2019;58:196–205. <https://doi.org/10.1002/mc.22919>.
 128. Liu SP, Yang JX, Cao DY, Shen K. Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. *Cancer*. 2013;10:138–41. <https://doi.org/10.7497/j.issn.2095-3941.2013.03.003>.
 129. Liu E, Liu Z, Zhou Y. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. *Int J Clin Exp Pathol*. 2015;8:3803–10.
 130. Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, Talpur HS, Yang L. Long non-coding RNAs: the new horizon of gene regulation in ovarian cancer. *Cell Physiol Biochem*. 2017;44:948–66. <https://doi.org/10.1159/000485395>.
 131. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. *Blood*. 2009;113(12):2835–42. <https://doi.org/10.1182/blood-2008-06-159541>.
 132. Kuznetsov HS, Marsh T, Markens BA, et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. *Cancer Discov*. 2012;2(12):1150–65. <https://doi.org/10.1158/2159-8290.CD-12-0216>.
 133. Power KA, McRedmond JP, de Stefani A, Gallagher WM, Gaora PO. High-throughput proteomics detection of novel splice isoforms in human platelets. *PLoS ONE*. 2009;4(3): e5001. <https://doi.org/10.1371/journal.pone.0005001>.
 134. Rowley JW, Oler AJ, Tolley ND, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. *Blood*. 2011;118(14):e101–111. <https://doi.org/10.1182/blood-2011-03-339705>.

135. Best MG, Sol N, Kooi I, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. *Cancer Cell*. 2015;28(5):666–76. <https://doi.org/10.1016/j.ccell.2015.09.018>.
136. Piek J, In 't Veld S, Best M, et al. EP457 Assessment of ovarian tumors with tumor educated platelets (TEPs). *Int J Gynecol Cancer*. 2019;29(Suppl 4):A291. <https://doi.org/10.1136/ijgc-2019-ESGO.516>.
137. Piek MJ. Early Detection of Ovarian Cancer and Treatment Response by Tumor Educated Platelets (TEP's) and Circulating Tumor DNA (CtDNA). ClinicalTrials.gov Identifier: NCT04022863. 2019-2023. <https://clinicaltrials.gov/ct2/show/NCT04022863>.
138. Giannakeas V, Narod SA. Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. *JAMA Netw Open*. 2021;4(8):e2120633. <https://doi.org/10.1001/jamanetworkopen.2021.20633>.
139. Shen J, Zhu X, Fei J, Shi P, Yu S, Zhou J. Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect. *Onco Targets Ther*. 2018;11:2831–41. <https://doi.org/10.2147/OTT.S159829>.
140. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell*. 2014;26(5):707–21. <https://doi.org/10.1016/j.ccell.2014.09.005>.
141. Ye SB, Li ZL, Luo DH, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. *Oncotarget*. 2014;5(14):5439–52. <https://doi.org/10.18632/oncotarget.2118>.
142. Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. *Nat Commun*. 2016;7:11150. <https://doi.org/10.1038/ncomms11150>.
143. Feng W, Dean DC, Hornicek FJ, Shi H, Duan Z. Exosomes promote pre-metastatic niche formation in ovarian cancer. *Mol Cancer*. 2019;18(1):124. <https://doi.org/10.1186/s12943-019-1049-4>.
144. Lobb RJ, Lima LG, Möller A. Exosomes: Key mediators of metastasis and pre-metastatic niche formation. *Semin Cell Dev Biol*. 2017;67:3–10. <https://doi.org/10.1016/j.semcdb.2017.01.004>.
145. Rivoltini L, Chiodoni C, Squaricina P, et al. TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. *Clin Cancer Res*. 2016;22(14):3499–512. <https://doi.org/10.1158/1078-0432.CCR-15-2170>.
146. Gobbo J, Marcion G, Cordonnier M, et al. Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. *J Natl Cancer Inst*. 2015;108(3):d3v330. <https://doi.org/10.1093/jnci/d3v330>.
147. Szajnik M, Derbis M, Lach M, et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. *Gynecol Obstet (Sunnyvale)*. 2013;Suppl 4:3. <https://doi.org/10.4172/2161-0932.54-003>.
148. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. *BMC Cancer*. 2009;9:244. <https://doi.org/10.1186/1471-2407-9-244>.
149. Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. *Gynecol Oncol*. 2007;107(3):563–71. <https://doi.org/10.1016/j.ygyno.2007.08.064>.
150. Liang B, Peng P, Chen S, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. *J Proteomics*. 2013;80:171–82. <https://doi.org/10.1016/j.jprot.2012.12.029>.
151. Wei W, Li N, Sun Y, Li B, Xu L, Wu L. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer. *Oncotarget*. 2017;8(14):23862–70. <https://doi.org/10.18632/oncotarget.13317>.
152. Anuradha S, Webb PM, Blomfield P, et al. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. *Med J Aust*. 2014;201(5):283–8. <https://doi.org/10.5694/mja14.00132>.
153. Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. *Oncotarget*. 2017;8(13):21429–43. <https://doi.org/10.18632/oncotarget.15249>.
154. Wang B, Yu L, Luo X, et al. Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. *Oncol Lett*. 2017;14(1):217–23. <https://doi.org/10.3892/ol.2017.6111>.
155. Wang B, Yu L, Yang GZ, Luo X, Huang L. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. *Asian Pac J Cancer Prev*. 2015;16(7):3003–7. <https://doi.org/10.7314/apjcp.2015.16.7.3003>.
156. Wu Y, Zhang X, Lin L, Ma XP, Ma YC, Liu PS. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. *Asian Pac J Cancer Prev*. 2014;15(3):1171–6. <https://doi.org/10.7314/apjcp.2014.15.3.1171>.
157. Zhang Q, Hu G, Yang Q, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. *Gynecol Oncol*. 2013;130(1):132–9. <https://doi.org/10.1016/j.ygyno.2013.04.048>.
158. Dong R, Yu J, Pu H, Zhang Z, Xu X. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. *J Int Med Res*. 2012;40(2):681–6. <https://doi.org/10.1177/147323001204000231>.
159. Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A, Murphy SK. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. *Gynecol Oncol*. 2011;123(3):581–7. <https://doi.org/10.1016/j.ygyno.2011.08.029>.
160. Liggett TE, Melnikov A, Yi Q, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. *Gynecol Oncol*. 2011;120(1):113–20. <https://doi.org/10.1016/j.ygyno.2010.09.019>.
161. Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. *Genome Med*. 2017;9(1):116. <https://doi.org/10.1186/s13073-017-0500-7>.
162. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Sci Transl Med*. 2012;4(136):136ra68. <https://doi.org/10.1126/scitranslmed.3003726>.
163. Pereira E, Camacho-Vanegas O, Anand S, et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. *PLoS ONE*. 2015;10(12):e0145754. <https://doi.org/10.1371/journal.pone.0145754>.
164. Parkinson CA, Gale D, Piskorz AM, et al. Exploratory Analysis of TP53 mutations in circulating tumour dna as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. *PLoS Med*. 2016;13(12):e1002198. <https://doi.org/10.1371/journal.pmed.1002198>.
165. Du ZH, Bi FF, Wang L, Yang Q. Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer. *Mol Genet Genomic Med*. 2018;6(4):638–47. <https://doi.org/10.1002/mgg3.414>.
166. Vanderstichele A, Busschaert P, Smeets D, et al. Chromosomal instability in cell-free dna as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. *Clin Cancer Res*. 2017;23(9):2223–31. <https://doi.org/10.1158/1078-0432.CCR-16-1078>.
167. Cohen PA, Flowers N, Tong S, Hannan N, Pertile MD, Hui L. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. *BMC Med*. 2016;14(1):126. <https://doi.org/10.1186/s12916-016-0667-6>.
168. Murtaza M, Dawson SJ, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*. 2013;497(7447):108–12. <https://doi.org/10.1038/nature12065>.
169. Thusgaard CF, Korsholm M, Koldby KM, Kruse TA, Thomassen M, Jochumsen KM. Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. *Gynecol Oncol*. 2021;161(3):884–95. <https://doi.org/10.1016/j.ygyno.2021.04.020>.
170. Giannopoulou L, Matoraki S, Buderath P, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. *Gynecol Oncol*. 2018;150(2):355–60. <https://doi.org/10.1016/j.ygyno.2018.05.026>.
171. Dvorská D, Braný D, Nagy B, et al. Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples. *Int J Mol Sci*. 2019;20(17):E4119. <https://doi.org/10.3390/ijms20174119>.

172. Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. *Int J Cancer*. 2009;124(2):387–93. <https://doi.org/10.1002/ijc.23957>.
173. Zhou F, Ma M, Tao G, et al. Detection of circulating methylated opioid binding protein/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma. *Clin Lab*. 2014;60(5):759–65. <https://doi.org/10.7754/clin.lab.2013.130446>.
174. SK S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. *Asian Pac J Cancer Prev*. 2019;20(10):3001–5. <https://doi.org/10.31557/APJCP.2019.20.10.3001>.
175. Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. *J Mol Diagn*. 2009;11(1):60–5. <https://doi.org/10.2353/jmoldx.2009.080072>.
176. Singh A, Gupta S, Badarukhiya JA, Sachan M. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer. *Int J Cancer*. 2020;147(6):1740–52. <https://doi.org/10.1002/ijc.32984>.
177. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science*. 2018;359(6378):926–30. <https://doi.org/10.1126/science.aar3247>.
178. No JH, Kim K, Park KH, Kim YB. Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. *Anticancer Res*. 2012;32(8):3467–71.
179. Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. *BMC Cancer*. 2012;12:325. <https://doi.org/10.1186/1471-2407-12-325>.
180. Barbosa A, Pinto P, Peixoto A, et al. Next generation sequencing of tumor and matched plasma samples: identification of somatic variants in ctDNA from ovarian cancer patients. *Front Oncol*. 2021;11: 754094. <https://doi.org/10.3389/fonc.2021.754094>.
181. Zhang X, Li H, Yu X, et al. Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker. *Cell Physiol Biochem*. 2018;48(5):1983–94. <https://doi.org/10.1159/000492521>.
182. Guo YX, Neoh KH, Chang XH, et al. Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. *Oncotarget*. 2018;9(7):7522–33. <https://doi.org/10.18632/oncotarget.23943>.
183. Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. *Gynecol Oncol*. 2011;122(3):567–72. <https://doi.org/10.1016/j.ygyno.2011.05.028>.
184. Pearl ML, Zhao Q, Yang J, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. *Gynecol Oncol*. 2014;134(3):581–90. <https://doi.org/10.1016/j.ygyno.2014.06.013>.
185. Pearl ML, Dong H, Tulley S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs). *Gynecol Oncol*. 2015;137(2):229–38. <https://doi.org/10.1016/j.ygyno.2015.03.002>.
186. Zhang W, Ou X, Wu X. Proteomics profiling of plasma exosomes in epithelial ovarian cancer: a potential role in the coagulation cascade, diagnosis and prognosis. *Int J Oncol*. 2019;54(5):1719–33. <https://doi.org/10.3892/ijo.2019.4742>.
187. Schwich E, Rebmann V, Horn PA, et al. Vesicular-Bound HLA-G as a predictive marker for disease progression in epithelial ovarian cancer. *Cancers (Basel)*. 2019;11(8):E1106. <https://doi.org/10.3390/cancers11081106>.
188. Arend RC, Londoño AI, Montgomery AM, et al. Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma. *Mol Cancer Res*. 2018;16(5):813–24. <https://doi.org/10.1158/1541-7786.MCR-17-0594>.
189. Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. *J Gynecol Oncol*. 2019;30(3): e32. <https://doi.org/10.3802/jgo.2019.30.e32>.
190. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. *Transl Oncol*. 2010;3(1):1–12. <https://doi.org/10.1593/tlo.09250>.
191. Della Pepa C, Tonini G, Santini D, et al. Low Grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. *Cancer Treat Rev*. 2015;41(2):136–43. <https://doi.org/10.1016/j.ctrv.2014.12.003>.
192. Sadlecki P, Antosik P, Grzanka D, Grabiec M, Walentowicz-Sadlecka M. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system. *Tumour Biol*. 2017;39(10):1010428317733984. <https://doi.org/10.1177/1010428317733984>.
193. Zhu J, Wong F, Szymiczek A. Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer. Under review.
194. Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. *Expert Rev Anticancer Ther*. 2017;17(12):1147–58. <https://doi.org/10.1080/14737140.2017.1398088>.
195. Minato T, Ito S, Li B, et al. Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125. *Gynecol Oncol Rep*. 2021;38: 100847. <https://doi.org/10.1016/j.gore.2021.100847>.
196. Judson PL, Geller MA, Bliss RL, et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. *Gynecol Oncol*. 2003;91(2):389–94. <https://doi.org/10.1016/j.ygyno.2003.08.004>.
197. Huang C, Lin X, He J, Liu N. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis. *Gynecol Oncol*. 2021;161(2):613–20. <https://doi.org/10.1016/j.ygyno.2021.02.024>.
198. Kolostova K, Matkowski R, Jędryka M, et al. The added value of circulating tumor cells examination in ovarian cancer staging. *Am J Cancer Res*. 2015;5(11):3363–75.
199. Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. *Int J Gynecol Cancer*. 2011;21(5):822–30. <https://doi.org/10.1097/IGC.0b013e318216cb91>.
200. Chebouti I, Kuhlmann JD, Buderath P, et al. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. *Oncotarget*. 2017;8(15):24303–13. <https://doi.org/10.18632/oncotarget.13286>.
201. Obermayr E, Bednarz-Knoll N, Orsetti B, et al. Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. *Oncotarget*. 2017;8(63):106415–28. <https://doi.org/10.18632/oncotarget.22468>.
202. Zuberi M, Mir R, Das J, et al. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. *Clin Transl Oncol*. 2015;17(10):779–87. <https://doi.org/10.1007/s12094-015-1303-1>.
203. Halvorsen AR, Kristensen G, Embleton A, et al. Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. *Dis Markers*. 2017;2017:3098542. <https://doi.org/10.1155/2017/3098542>.
204. Paracchini L, Beltrame L, Grassi T, Inglesi A, Fruscio R, Landoni F, Ippolito D, Delle Marchette M, Paderno M, Adorni M, Jaconi M, Romualdi C, D'Incalci M, Siravegna G, Marchini S. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer. *Clin Cancer Res*. 2021;27(9):2549–59. <https://doi.org/10.1158/1078-0432.CCR-20-3345>.
205. Swanton C. Intratumor heterogeneity: evolution through space and time. *Cancer Res*. 2012;72(19):4875–82. <https://doi.org/10.1158/0008-5472.CAN-12-2217>.
206. Burrell RA, Swanton C. The evolution of the unstable cancer genome. *Curr Opin Genet Dev*. 2014;24:61–7. <https://doi.org/10.1016/j.gde.2013.11.011>.
207. Greaves M, Maley CC. Clonal evolution in cancer. *Nature*. 2012;481(7381):306–13. <https://doi.org/10.1038/nature10762>.
208. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. *Ann Oncol*. 2016;27(8):1449–55. <https://doi.org/10.1093/annonc/mdw142>.

209. Tan DSP, Kaye SB. Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different? *Am Soc Clin Oncol Educ Book*. 2015;35(1):114–21. https://doi.org/10.14694/EdBook_AM.2015.35.114.
210. Benner SE, Wahl GM, Von Hoff DD. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. *Anticancer Drugs*. 1991;2(1):11–25. <https://doi.org/10.1097/00001813-199102000-00002>.
211. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. *Nature*. 2015;521(7553):489–94. <https://doi.org/10.1038/nature14410>.
212. Lin KK, Harrell MI, Oza AM, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. *Cancer Discov*. 2019;9(2):210–9. <https://doi.org/10.1158/2159-8290.CD-18-0715>.
213. Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. *J Clin Oncol*. 2017;35(12):1274–80. <https://doi.org/10.1200/JCO.2016.70.4627>.
214. Weigelt B, Comino-Méndez I, de Bruijn I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. *Clin Cancer Res*. 2017;23(21):6708–20. <https://doi.org/10.1158/1078-0432.CCR-17-0544>.
215. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. *Clin Cancer Res*. 2004;10(13):4420–6. <https://doi.org/10.1158/1078-0432.CCR-03-0732>.
216. Capizzi E, Gabusi E, Grigioni AD, De Iaco P, Rosati M, Zamagni C, et al. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. *Diagn Mol Pathol*. 2008;17(1):34–8. <https://doi.org/10.1097/PDM.0b013e3181359e1f>.
217. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. *Cancer*. 2010;116(8):1918–25. <https://doi.org/10.1002/cncr.24997>.
218. Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. *Int J Cancer*. 2011;128(11):2572–80. <https://doi.org/10.1002/ijc.25602>.
219. Choudhuri S, Sharma C, Banerjee A, Kumar S, Kumar L, Singh N. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. *MolCellBiochem*. 2014;386(1–2):25969. <https://doi.org/10.1007/s11010-013-1863-8>.
220. Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho C, Pereira E, Lin L, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. *Neoplasia*. 2014;16(1):97–103. <https://doi.org/10.1593/neo.131900>.
221. Flanagan JM, Wilson A, Koo C, Masrouf N, Gallon J, Loomis E, et al. Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. *Clin Cancer Res*. 2017;23(9):2213–22. <https://doi.org/10.1158/1078-0432.ccr-16-1754>.
222. Ratajska M, Koczkowska M, Zuk M, Gorczynski A, Kuzniacka A, Stukan M, et al. Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer. *Oncotarget*. 2017;8(60):101325–32. <https://doi.org/10.18632/oncotarget.20722>.
223. Morikawa A, Hayashi T, Shimizu N, Kobayashi M, Taniue K, Takahashi A, et al. PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. *Oncotarget*. 2018;9(20):15266–74. <https://doi.org/10.18632/oncotarget.24555>.
224. Oikkonen J, Zhang K, Salminen L, et al. Prospective Longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer. *JCO Precis Oncol*. 2019;3(1):12. <https://doi.org/10.1200/PO.18.00343>.
225. Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, Toujima S, et al. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAnCer personalized profiling by deep sequencing. *Sci Rep*. 2019;9(1):10426. <https://doi.org/10.1038/s41598-019-47030-w>.
226. Noguchi T, Sakai K, Iwahashi N, Matsuda K, Matsukawa H, Yahata T, et al. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer. *Oncol Lett*. 2020;19(4):2713–20. <https://doi.org/10.3892/ol.2020.11356>.
227. Han MR, Lee SH, Park JY, Hong H, Ho JY, Hur SY, et al. Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer. *Cancer Res Treat*. 2020;52(3):779–88. <https://doi.org/10.4143/crt.2019.700>.
228. Alves MC, Fonseca FLA, Yamada A, Barros L, Lopes A, Silva L, et al. Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: a pilot study. *Tumour Biol*. 2020;42(5):1010428320919198. <https://doi.org/10.1177/1010428320919198>.
229. Otsuka J, Okuda T, Sekizawa A, et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. *Int J Gynecol Cancer*. 2004;14(3):459–64. <https://doi.org/10.1111/j.1048-891x.2004.014305.x>.
230. Vencken PMLH, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. *Ann Oncol*. 2011;22(6):1346–52. <https://doi.org/10.1093/annonc/mdq628>.
231. Liu X, Chan D, Ngan H. Mechanisms of chemoresistance in human ovarian cancer at a glance. *Gynecology and Obstetrics*. 2012;2(3):e104. <https://doi.org/10.4172/2161-0932.1000e104>.
232. Liu X, Gao Y, Lu Y, Zhang J, Li L. Oncogenes associated with drug resistance in ovarian cancer. *J Cancer Res Clin Oncol*. 2014;141:381–95.
233. Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. *Oncol Rep*. 2014;31:745–54.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

